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Abstract 
Sphingolipids are important structural components of eukaryotic membranes, in 
addition they and their precursors are involved in signal transduction processes. In 
eukaryotes the biosynthetic pathway of sphingolipid biosynthesis is largely conserved. 
However, whilst mammals produce sphingomyelin (SM) as the major 
phosphosphingoUpid using the enzyme SM synthase, plants and many pathogenic 
fungi and protozoa synthesize inositol phosphorylceramide (IPC) by IPC synthase. 
This enzyme is a target for anti-fungal drugs and functional orthologues have recently 
been identified in the insect vector-borne pathogenic kinetoplastid protozoa. These 
parasites are responsible for a range of neglected diseases and Trypanosoma brucei are 
the cause human African trypanosomiasis in many regions of Africa. The available 
treatments for this disease are limited, often demonstrate severe side-effects and drug 
resistance is increasing. T. brucei sphingolipid synthase (TfcSLS), a functional 
orthologue of the yeast IPC synthase, may be a target for novel anti-protozoals drugs. 
Here I show that this enzyme functions as an IPC synthase both in vitro and ex vivo. 
Furthermore, the T&SLS is essential for parasite growth and can be inhibited in vitro by 
a known anti-fungaL Perhaps most importantly this drug demonstrates rapid 
trypanocidal activity against bloodstream form parasites. Thus TbSLS is a promising 
drug target. 
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Chapter 1: 
Introduction 
Chapter 1: Introduction 
1.1 Trypanosoma brucei and disease 
1.1.1 General information 
Trypanosoma brucei (Kinetoplastae, Trypanosomatidae) are unicellular eukaryotes that 
infect both human and economically important animals causing African sleeping 
sickness in sub-Saharan African (Raper et al., 2002). This tsetse fly-borne disease is 
classified as a u-opical disease research (TDR) category 1 resurgent disease by the 
World Health Organization (WHO; Barren et al., 2003). 
According to the WHO, the people of 36 sub-Saharan countries are threatened by this 
disease and 300,000 new cases are reported every year (Masocha et al., 2007). It is 
estimated that 50000 people died following infection by T. brucei each year. (Fairlamb, 
2003) Around 1 million people died from African sleeping sickness disease between 
1896 and 1908 (Seed, 2001). However, during the 1950s, this disease was controlled 
using DTT to kill the vector and the progress of medical technology (Seed, 2001). 
Therefore, the number of cases decreased rapidly between 1949 and 1965 (figure 1.1). 
However, in the modem era, African sleeping sickness is out of control because of, 
amongst other things, war and the associated mass migration of people (Kennedy, 
2004) . 
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Figure 1.1 
Newly registered cases of sleeping sickness, annually reported to WHO. 
(http://wvm.who.int/wer/2006/wer8108 .pdf) 
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Figure 1.2 
Human African trypanosomiasis endemicity in Africa (Barret et al., 2007). 
Red: more than 1000 cases were reported per year. Orange: About 50 to 1000 
cases were reported per year. Blue: less than 50 cases were reported per year. 
Green: currently report no case of HAT. 
There are two subspecies of African trypanosome that cause disease in humans: T. b. 
gambiense and T. b. rhodesiense. T. b. brucei causes Ngana in cattle, an economicalJy 
important disease in sub-Saharan Africa, but cannot infect human because the parasite 
is lysed by components of the high-density lipoprotein fraction of human blood (Rifkin, 
1978). 
T. b. gambiense which causes West African Trypanosomiasis can be found in central 
and western African countries such as Sudan, Angola and Gabon (figure 1.2). T. b. 
rhodesiense which causes East African Trypanosomiasis can be found in central and 
eastern African countries such as Kenya, Tanzania and Malawi (figurel.2, 
http://www.cdc.gov/). 
Ninety percentage of African sleeping sickness cases are caused by T. b. gambiense 
and lead to a chronic infection (Barrett et al., 2003). Following a tsetse fly bite, the 
incubation period can be several months or years and when this disease is detected, the 
patient's central nervous system may already be damaged and the condition can 
become very dangerous. Other 10% of cases are caused by T. b. rhodesiense and lead 
to an acute infection (Parry et al., 2003). The appearance of symptoms can be few 
weeks or months after infection and the parasites invade can the central nervous 
system very rapidly (http://www.cdc.gov/). 
1.1.2 T. brucei l i fe cycle 
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Figure 1.3 
T. brucei life cycle from CDC (Kennedy, 2004). 
The fransmission of this trypanosome is caused by the bite of tsetse fly {Glossina spp.) 
which can be found in the grass near lakes or rivers, and in the forests and savarmah of 
Africa (Parry et al., 2003). 
After the fly bites a human (step 1), metacyclic frypanosomes fransform into 
bloodsfream form and start to fransform the metacyclic variable surface glycoprotein 
(VSG) into the first bloodsfream form VSGs at the site of inoculation (step 2, 
Donelson et al., 1985). This pathogenic form proliferates in the bloodsfream (step 3) 
and can subsequently enter the lymph node and spinal fluid. At this stage, parasites can 
also be transmitted to non-infected Tsetse flies (step5, http://www.cdc.gov/) where they 
fransform to the procyclic form, losing the VSG coat, and replicate in the mid-gut of 
the vector (step 6). After 3 weeks, the procyclic forms migrate to the salivary (step 7) 
and transform into the metacyclic form which reqacuires the VSG coat (step 8, 
Donelson et al., 1985). In addition, some reports showed that this parasite could also 
infect the foetus via the placenta and also be fransmitted by contaminated needles 
(WHO, 2005). 
1.1.3 Clinical features 
Five days after infection, chancre may occur, especially in T. b. rhodesiense infection, 
at die site of the tsetse bite (figure 1.4; Barrett et al., 2003, Parry et al., 2003). This 
symptom is caused by the inflammatory response to the Trypanosomes (Naessens et al., 
2003). Subsequentiy, there are two stages of African sleeping sickness: the 
haemolymphatic stage and the encephalitic stage. 
Haemolymphatic stage. After one to three weeks, symptoms are nonspecific. The 
parasites escape from human adaptive immune response by antigenic variation via 
V S G which prevents trypanosome lysis by complement alternative pathway 
(Vincendeau and Bouteille, 2006, Maser et al., 2003) and cause fever, malaise, 
arthralgia, weakness and weight loss (Sternberg, 2004). Many organs are infected by 
the bloodstream form trypanosomes at this stage, including the liver, skin, eye and 
cardiovascular system (Barrett et al., 2003). This plethora of symptoms can make 
initial diagnosis difficult; for example, patients are often misdiagnosed as suffering 
from malaria and so given anti-malarials (Parry et al., 2003, Kennedy, 2006). In T. b. 
gambiense infection, the major symptom is the enlargement of lymph nodes, especially 
in die Unangle of die neck (Parry et al., 2003). 
Encephalitic stage. At diis stage, the parasites cross the blood-brain barrier are 
detectable in the cerebrospinal fluid (CSF) and cause damage to the central nervous 
system (Enanga et al., 2002). How the parasites cross blood-brain barrier is stUl 
unknown, however, it is assumed that T. brucei enter the central nervous system (CNS) 
by an active process (peneu-ation) similar to white blood cells (Masocha et al., 2007). 
Again, it is difficult to diagnose the onset of this stage without examining the C S F for 
the presence of parasites. Patients' could change behavior becoming agitated and 
apathetic with severe headache, perhaps, losing the ability to eat and drink (Parry et al., 
2003). Untreated, patients fall into a coma and die (Sternberg, 2004). 
Figure 1.4. 
Trypanosoma! chancre on shoulder. 
1.1.4 Immune response 
As well as facilitating immune evasion through antigenic variation, VSG also plays an 
important role in the human immune response to the trypanosomes. A trypanosome 
cell is covered with 10 molecules VSG attached to its surface membrane by a 
glycosylphosatidyl-inositol (GPl) anchor. Here they act as the immune-dominant 
antigen activating both Th and B cells (Mansfield, 1994). The GPI-moiety of soluble 
VSG released Irom the parasite directly leads to the over-activation of macrophages, 
which then produce TNF-a after stimulation with IFN-yprobably produced fi-om CD4+ 
T cells. TNF-a subsequently induces CD8+ T cells to produce high levels of IFN-y 
leading to a decrease in the formation of lL-2 and IL-2 receptors thus impairing the 
proliferative T cell response, causing immune-suppression and avoiding parasite 
elimination (Sternberg, 2004; Zambrano-Villa et al., 2002). In addition, increasing 
levels of IL-10 were observed in the CSF at the late stage of T. brucei infection related 
to the inflammatory response and the effects of NO synthesis (MacLean et al., 2001, 
Vincenedau and Bouteille, 2006). 
The cattle parasite, T. b. brucei, is unable to infect humans due to the presence of 
trypanosome lytic factor (TLF) in sera (Raper et al., 2001). Unlike T. b. brucei, T. b. 
rhodesiense has a serum resistance associated (SRA) gene which encodes a protein 
protecting the parasites against TLF-mediated lysis and so avoids clearance from the 
bloodstream. However, T. b. gambiense lacks the SRA gene and is resistant to TLF via 
an unknown mechanism (Gibson, 2002). 
In a further immune evasion strategy, trypanosomes produce a gp63-like protein 
similar to gp63 from Leishmania (Donelson et al., 1998), which is believed to protect 
bloodstream form parasites f rom complement-mediated lysis (Zambrano-Villa et al., 
2002). 
1.1.5 Diagnosis 
African sleeping sickness cannot be easily diagnosed due to the non-specific 
symptoms and multiple tests are often necessary (Kennedy, 2004). At the first, 
haemolymphatic stage, of the disease parasites can be detected in blood or infected 
tissue, such as lymph nodes, by staining and light microscopy (figure 1.5 and figure 
1.6, Kennedy, 2004). However, this method is often initially invalid for T. b. 
gambiense as the infection is chronic and parasites appear at the peripheral rather than 
blood circulatory system (Kennedy, 2004). Under these circumstances, the 
antibody-detecting, card agglutination trypanosomiasis test (CATT) is the easiest and 
simplest way to reach a diagnosis (WHO, 2005). No infection is diagnosed when 
CATT is negative or the titre is less than 1:4, a positive diagnosis is reached when 
CATT is positive and the titre is more than 1:16. Following a positive CATT, it is 
necessary to check blood smears to confirm the presence of parasites before initiating 
treatment (Chappuis et al., 2005). 
At the second, encephalitic stage, CSF extracted by lumbar puncture can allow the 
parasites to be detected directly. (Parry et al., 2003) An increase in the white blood cell 
count to more than 5/}J1 is also indicative and is a rise in IgM levels, as measured by a 
latex agglutination assay (Lejon et al., 2002). PCR of CSF can be an additional and 
sensitive diagnostic tool (Solano et al., 2002), however, its expense negates its use in 
many endemic countries. As an alternative, loop-mediated isothermal amplification 
(LAMP), in which DNA in amplified under isothermal (constant temperature) 
conditions of around 65 °C, has been used negating the need for the costly 
thermocyclers required for PCR (Kuboki et al., 2003). 
Neither computerized tomographic (CT), magnetic resonance (MR) nor 
electroencephalogram (EEC) showed any neurological abnormalities at this disease 
stage (Atouguia and Kennedy, 2000). However, the variafion of brain activity indicated 
by rapid eye movement (REM) may be informative (Buguet et al., 2005). 
Figurel.5 
T. brucei in human blood; thin film, 
Giemsa stain (Parry et al., 2003). 
Figure 1.6 
Colored scanning electron micrograph of 
T. brucei in human blood (Kennedy, 
2004). 
There are four main drugs which have been used in the different stages in the disease: 
Suramin, Pentamidine, Melarsoprol and Eflomithine (DFMO). Three of them were 
established as treatments more than 50 years ago, with DFMO appearing more than 25 
years ago (table 1.1, Vmcendeau and Bouteille, 2006). 
Suramin which is a water soluble colourless, polyanic sulfonated naphthylamine was 
introduced in the 1920s (Fairiamb, 2003). This drug, whose mechanism of action is 
unknown, is used to treat stage 1 T. b. rhodesiense infection but cannot efficiently 
penetrate the human blood-brain barrier (BBB) and so in ineffective in stage 2 
(Fairiamb, 2003). Suramin is believed to inhibit topoisomerase II and interfere with 
white blood cell signaling in animal cells (Bojanowski et al., 1992). The side effects 
these interactions appear to cause include collapse, nausea, vomiting and shock. More 
seriously, latent kidney damage can occur leading to, for example, haemolytic anaemia 
which can prove fatal (Fairiamb, 2003). Although some cases showed that this drug 
may threaten the patient's life, it remains a first line treatment for early phase T. b. 
rhodesiense infections (Parry et al., 2003). 
Pentamidine, which is an aromatic diamidine, was introduced in the 1940s (Fairiamb, 
2003). Again, this drug cannot penetrate human BBB and therefore is only effective 
against stage 1 African sleeping sickness. Pentamidine enters the parasites via the P2 
aminopurine permease which also transports melarsoporal (see below. Carter et al., 
1995). In addition, pentamidine can be transported by high-affinity pentamidine 
transporter 1 (HAPTl) and a low-affinity pentamidine transporter 1 (LAPTl ) . 
Therefore, trypanosomes resistant to melarsoporal are still inhibited by pentamidine 
(de Koning, 2001). However, pentamidine is only used as a frontline treatment against 
T. b. gambiense as it is less reliable in the treatment of T. b. rhodesiense infections, 
where it is only used i f suramin is not tolerated (Parry et al., 2003; Pepin and Milord, 
1994). Pentamidine may cause organ damage of the liver, kidney and pancreas 
(Fairlamb, 2003). In addition, intravenous injection may lead to hypotensive reaction 
and therefore, this drug is administered intramuscularly (Fairlamb, 2003). The 
mechanism of action of pentamidine involves the inhibition of the T. brucei 
topoisomerase and so parasite replication (Shapiro and Englund, 1990). 
Melarsoprol was developed in 1949 (Kennedy, 2004). The use of this drug is very 
extensive in the treatment of both T. b. rhodesiense and T. b. gambiense stage 2 
infections. Melarsoprol is virtually insoluble in water, and is administrated 
intravenously. (Fairlamb, 2003) It is known to inhibit the glycolytic enzyme, 
phosphogluconate dehydrogenase (Van Schaftingen et al., 1987, Hanau et al., 1996) 
and kills the parasite very quickly. However, it is also a very toxic and dangerous 
treatment (Parry et al., 2003). Side effects include vomiting, abdominal colic, 
arthralgia and thrombophlebitis. Furthermore, 5-10% patients suffer severe 
post-treatment reactive encephalopathy (PTRE) which is often fatal (Fairlamb, 2003, 
Pepin and Milord, 1994). Moreover, drug resistance caused by the disablement of the 
P2 aminopurine permease transporter is increasing (Delespaux and Koning, 2007). 
Melarsoprol resistance has now been found in the north west of Angola, north west of 
Uganda and south Sudan (Brun et al., 2001). 
Eflomidiine (Difluoromethylomithine; DFMO) was developed as an anti-tumor drug 
(Tabor and Tabor, 1984, Delespaux and de Koning, 2007) has been employed in die 
treatment of African sleeping sickness from 1981 (Kennedy, 2004). DFMO is an 
inhibitor of die first step of polyamide synthesis: ornithine decarboxylase (ODC) which 
catalyses the formation of putrescine from ornithine. The reason for its efficacy against 
African trypanosomes is unclear given that DFMO also inhibits the mammalian ODC. 
However, differences in the turnover rate of ODC in mammals and parasites may 
10 
provide an explanation (Heby, 2003). Similarly, the high turnover rate of ODC in T. b. 
rhodesiense compared with T. b. gambiense may explain why the former in insensitive 
to DFMO and the drug is only used to treat the late stage of infection with T. b. 
gambiense (Iten et al., 1997). In infection with this subspecies, DFMO has a greater 
affect on T. b. gambiense infection than melarsoprol, in addition it demonstrates much 
less toxicity and can be taken orally (Fairiamb, 2(K)3). However, the high cost of this 
drug restricts its availability to patients with African sleeping sickness (Parry et al., 
2003). 
Nifurtimox was developed in 1977 and is used to treat Qiagas disease, which is caused 
by American trypanosomes (Delespaux and de Koning, 2007). Nifurtimox maybe 
combined with DFMO to treat African sleeping sickness when melarsoprol or DFMO 
treatment was fails (Bray et al., 1994, Barrett et al., 2007). However, the efficiency of 
this drug is still under evaluation (Kennedy, 2004). 
Following drug treatment, patients should receive follow up examinations every six 
months for at least two years, something very challenging in the endemic 
environments (Kennedy, 2004). The variation of VSG means a viable vaccine (the 
ideal situation) is unlikely to be developed (Matovu et al., 2003). This together with 
increasing drug resistance and the severe side effects (including death) of existing 
treatments mean it is necessary to urgently develop new drugs to treat the African 
sleeping sickness (Maser et al., 2003). 
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Drug Spectrum Indication 
Year of first Route of 
use Adinistration 
Suramin T. b. rhodesiense Stage 1 1920s i.v. 
Pentamidine T. b. gambiense Stage 1 1940 i .m. 
Melarsoproi T. b. rhodesiense 
(MelB) T. b. gambiense 
Stage 2 1949 i.v. 
Eflornithine 
(DFMO) 
T. b. gambiense Stage 2 1981 I.v. 
Table 1.1 
Drugs currently used for the treatment of Human African Trypanosomiasis, 
i.v. - intra-venous; i.m - intra-muscular (Kermedy, 2004) 
1 2 
1.2 Sphingolipids 
1.2.1 Introduction 
Sphingolipids (SLs) were named because of their enigmatic, 'sphinx-like' properties 
by J. L . W. Thudichum who discovered this membrane component in 1884 (Futerman 
and Hannun, 2004). These lipid species can be found in aU eukaryotic cells (Hannun et 
al., 2001) and have been demonstrated to be pivotal in signal transduction and cell 
membrane architecture (Futerman and Riezman, 2005). 
Animals, including mammals, produce the phosphosphingolipid (PSL) sphingomyelin 
(SM) via the enzyme SM synthase (Huitema et al., 2004). However, plants, yeast and 
some protozoa produce inositol phosphorylceramide (IPC) via IPC synthase (Becker 
and Lester., 1980). Unlike the synthesis of sterols and glycerolipids, SL biosynthesis 
begins in die endoplasmic reticulum (ER) with the production of the unmodified 
sphingolipid ceramide, and then proceeds in the Golgi apparatus with synthesis of 
complex species (Futerman and Riezman, 2005). 
In humans, SLs are associated with diseases including diabetes (Sunmiers, 2005), 
some cancers (Modrak et al., 2006) and infection by microorganisms (Cowart and 
Obeid, 2006) in various ways. This evident importance has led to increasing research 
efforts focusing on the understanding of SL metabolism and function. 
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1.2.2 Structure of sphingolipids 
The basic structure of SL consists of a long-chain sphingoid base connected to a fatty 
acid at the second carbon (C-2) by an amide bond (figure 1.7, Heung et al., 2006, 
Futerman and Hannun, 2004). 
Complex PSLs are amphipathic molecules that contain both hydrophobic and 
hydrophilic regions (Futerman and Hannun, 2004). These hydrophobic (polar) groups 
are attached at the C-1 position of die sphingoid base through an ester bond (figure 1.7, 
Heung et al., 2006, Futerman and Hannun, 2004). Alternatively, the sphingoid base can 
be connected to one or more saccharide groups including glucose, galactose and 
N-acetylgalatosamine via a glycosidic bond to form complex, neutral 
glycosphingolipids (GSLs; figure 1.7, Masserini and Ravasi, 2001, Futerman and 
Hannun, 2004). 
In yeast, sphingoid bases such as phytosphingosines and sphinganines carry 18-20 
carbon atoms (CI8-20; Menr i l , 2002, Rao et al., 2007). In mammals, die major SLs 
contain a CI8 sphingoid base (Shayman, 2000) compared to C14 in insects (Lester and 
Dickson, 1993) and CI6 in nematodes (Holthuis et al, 2001). More dian 20 kinds of 
fatty acids can be found attached to the sphingoid base leading to a wide variety of SL 
species (Futerman and Riezman, 2005, Futerman and Hannun, 2004). 
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Sphingosine Ceramide Sphingomyeliii IPC 
Figure 1.7 
Structure of sphingolipids (Futerman and Hannun, 2004). 
1.2.3 Function 
SLs play an important role in eukaryotic cells participating in the endo- and exocytosis 
signaling and cell-cell interactions (Rao et al, 2007). SLs in animals together with 
sterols, form lipid raft microdomains which mediate the recruitment of certain 
lipidated proteins to form receptors which mediate signal transduction, cell adhesion, 
migration and proliferation (Holthuis et al., 2001). However they also play a role in the 
resistance to chemotherapy (e.g. of anti-cancer drugs) and act as portals for 
microorganisms such as bacteria and viruses to enter the mammalian cell (Heung et al., 
2006; Futerman and Hannun, 2004). In other eukaryotes, notably the fiingi, SLs 
mediate the heat stress response, signal fransduction and the pathogenesis of certain 
medically important species (Heung et al, 2006). 
Furthermore, ceramide, the simplest SL in all eukaryotic cells, is found to promote cell 
apoptosis and inhibit cell proliferation (Futerman and Hannun, 2004). 
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1.2.4 Biosynthetic pathway 
1. Ceramide synthesis (figure 1.8) 
The first, rate-limiting step of sphingolipid synthesis is the reaction of L-serine and 
palmitoyl Co-A to form 3-ketosphingosine which is catalyzed by serine 
palmitory-transferase (SPT), the gene products of L C B l and LCB2 in yeast (Nagiec et 
al, 1994). Subsequently, 3-ketosphingosine is reduced to form sphinganine by 
3-ketosphingosine reductase which is encoded by TSCIO (Cowart and Obeid, 2007, 
Beeleretal., 1998). 
In animal cells, sphinganine is N-acylated to form dihydroceramide and trans-double 
bonds are inserted at the 4, 5 position of sphinganine group to form ceramide (Merrill 
et al., 1997). In yeast, sphinganine is hydroxylated to form phytosphingosine (Grilley 
et al., 1998). (Phyto)ceramide is subsequently incorporated into many SLs such as 
ceramide-1-phosphate, SM and GSLs. 
2. Sphingomyelin synthase (figure 1.19) 
The formation of ceramide occurs in the ER (Rao and Acharya, 2007) and it's 
transported from ER to Golgi apparatus by a specific ceramide transport molecule 
(CERT; Hanada et al., 2003) in animal cells. After that, Phosphocholine is transferred 
from phosphatidylcholine (PC) to ceramide to form SM in Golgi apparatus and at the 
plasma membrane (Futerman and Hannun, 2004). SM can also be degraded into 
ceramide by sphingomyelinase (SMase), a process which regulates cell growth and 
apoptosis (Hannun and Luberto, 2004). 
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Figure 1.8 
Pathway of ceramide synthase (Holthuis et al., 2001). The formation of 
creamide is in mammals and phytoceramide in yeast or plants. 
Ceramide 
SMase OH 
phosphocholine 
Figure 1.9 
Pathway of SM synthesis (Futerman and Hannun, 2004). Phosphocholine is 
transferred from phosphatidylcholine (PC). 
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3. Inositol ceramide synthesis (figure 1.10) 
In yeast, plants and some protozoa, the phosphoinositol head-group from 
phosphatidyl inositol (PI) is transferred to phytoceramide to form inositol 
phosphorylceramide (IPC), a process catalyzed by IPC synthase ( A U R l p in yeast). 
Like mammals, the complex sphingolipid, IPC, is synthesized in die Golgi apparatus 
(Levine et al., 2000; Denny et al. 2006). In yeast, IPC is subsequently mannosylated by 
the gene products of CSGl, CSG2 and CSHl to form mannoseinositol 
phosphor-ceramide (MIPC, Beeler et al., 1997). SubsequenUy, another inositol 
phosphate is added to MIPC to form mannose inositol (P)2 ceramide (M(JP)2C), a 
process regulated by the enzyme encoded by Ipt l (Dickson et al., 1997). 
Phytoceramide 
inositol phosphate 
nositol phosphorviceramlde 
SURl/CSGl 
MIPC 
Inostol phosphate 
OH 
j-P-lnofitol 
OHNH , 1 
Mannose 
OH 
IPTl 
OH 
M(,P),c -j„y'T' 
Lf^ Uamose 
OH 
Figure 1.10 
Pathway of IPC synthesis (Beeler et al., 1997). Genes are shown in capital 
italitics. 
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1.2.5 Sphingolipid biosynthesis as a drug target 
So far, 11 enzmyes have been found to be involved in SLs metabolism (Futerman and 
Riezman, 2005). SPT, the fu^t enzyme in the pathway, belongs to the pyridoxal 
phosphate-dependent a-oxoamine synthase family. Drugs are known to specifically 
inhibit the function of SPT: sphingofungin, lipoxamycin and myriocin (figure 1.11, 
Delgado et al., 2006). In addition, ceramide synthesis can be inhibited by fiingi 
metabolites such as fumonisin produced by Fusarium verticilloides (figure 1.12, Desai 
et al., 2002), the fumonisin-like AAL-toxin produced by Altemaria alternate var. 
lycopersici (figure 1.12,Winter et al., 1996) and australifungins from Aporormiella 
australis. (Mandala et al., 1995) 
IPC synthase activity is evident only in yeast, plants and protozoa rather than animal 
cells. The inhibition of IPC synthase has become an important target in the fight 
against these pathogens (Nagiec et al., 1997). Inhibition by aureobasidin A (produced 
by Aureobasidium pullulans, Zhong et al., 2000) has been demonstrated in many yeast 
and fungi including S. cerevisiae, and the pathogenic Candida and Aspergillus species 
(Zhong et al., 2000). Kinetoplastid parasites including Leishmania major (Heung et al., 
2006) and Trypanosoma cruzi (Figueiredo et al., 2005) also have IPC synthase activity 
and reports indicate that aureobasidin A successfully inhibits the IPC synthase f rom 
these protozoan parasites (Denny et al., 2006, Figueiredo et al., 2005). Therefore, IPC 
synthase represents a new drug target for the pathogenic protozoa. 
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Figure 1.11 
Structure of drugs used to inhibit SPT (Delgado et al., 2006). These 
compounds react with SPT to interfere the the catalytic reaction. 
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Figure 1.12 
Structure of drugs used to inhibit ceramide synthase (Delgado et al., 2006). 
Both inhibitors bind to the dicarboxylix acid side chains on the sphingoid base 
substrate. 
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1.3 The Trypansoma brucei sphingolipid synthase 
The identification of kinetoplastid IPC synthase (Denny et al., 2006) has made 
possible: i) its validation as an anti-protozoal target; and ii) the establishment of die 
specific efficacy of known fungal IPC synthase inhibitors. The T. brucei database 
contains four closely related orthologues of the characterised Leishmania IPC synthase 
(Denny et al., 2006). Previously, mass spectrometry of lipid fractions has shown that 
whilst the major phosphosphingolipid in pathogenic bloodstream form parasites is SM 
(Patniak et al., 1993; Richmond et al., 2007a; Richmond et al., 2007b); insect stage, 
procyclic T. brucei also contain, like Leishmania, IPC (Giither et al, 2006). 
This report describes the characterization of the T. brucei, sphingolipid synthase 
(TTJSLS) which demonstrates itself to be an IPC synthase, but with the further ability to 
mediate the production of 2 other unknown sphingolipids (X - co-migrating with SM; 
and Y ) . The IPC synthase activity of TbSLS is acutely sensitive to the fungal inhibitor 
aureobasidin A and bloodstream form T. brucei are rapidly killed at sub-micromolar 
concentrations of this drug. Down-regulation of TfcSLS, using inhibition RNA (RNAi), 
in bloodstream form parasites demonstrated that the enzyme activity is essential for 
growth thus validating it as a target for the development of new therapies. 
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1.4 What is R N A i ? 
The interference RNA (RNAi) response was first identified in plants (Napoli et al., 
1990) and is a natural biological protective response to viral dsRNA (Sledz and 
Williams, 2005). However, since Fire et al (1998) injected dsRNA into Caenorhabditis 
elegans and found that gene expression could be specifically inhibited the technology 
o f R N A i , in which the Dicer and RISC complexes play an important role, has 
developed very quickly as tool for studies o f gene fiinction (Geley and Muller, 2004). 
R N A i now is found to fiinction in many eukaryotic organisms such as Drosophila, 
hydra, zebrafish, mammals and Trypanosoma brucei (table 1.2, Brantl, 2002). 
kingdom species Stage tested Delivery method 
Protozoans Trypanosoma brucei Procyclic and Transfection 
bloodstream forms 
Toxoplasma gondii Mature form in Transfection 
fibroblast 
Invertebrates Drosophila melanogaster Cell lines, adult and Injection for adult and embryo 
embryo stage,soaking and transfection 
for cell lines 
Hyfra Adult Delivered by micropipette 
Vertebrates Zebra fish Embryo Microinjection 
Mice Prenatal, embryonic Injection 
stages and adult 
Human Human ceU lines Transfection 
Plants Onocots/dicots Plant Particle bombardment with 
siRNA/transgenics 
Fungi Neurospora crassa Filamentous fungi Transfection 
S. pombe Filamentous fungi Transgene 
Algae Chlamydomonas reinhardtii Transfection 
Table 1.2 
Eukaryotic organisms exhibiting RNA-related phenomena. (Brantl, 2002) 
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Chapter 2: 
Materials and Methods 
Chapter!: Materials and methods 
2.1 Materials 
2.1.1 Chemicals 
Tris/HCI, glucose, ammonium sulphate, galactose, KCl , lithium acetate, raffinose, 
tryptophan, P-mercaptoethanol, NaCl, chloroform (A.C.S), methanol (A.C.S) and 
acid-washed glass beads (425-600um, 30-40 U.S. sieve) were from Sigma Aldrich. 
Yeast nitrogen base and BODIPY FL-ceramide were from Invitrogen 
HMI-9 powder, penicillinystreptomycin, foetal bovine serum and L-glutamine were 
from GIBCO BRL. 
G418, agarose, tryptone and yeast extract were from Melford. 
Amino acids drop-out supplement -HIS-URA-TRP was from Clontech. 
Complete EDTA-free protease inhibitor cocktail tablets and HPTLC plates were from 
Merck. 
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2.1.2 Buffers 
Solution Final cone. Volume Stock solution 
S T E 25 m M 1.25 ml Tris/HCL(1M) 
(50ml) 250niM 12.5m] Sucrose(]M) 
I m M 100^1 EDTA(0.5M) 
1 tab Complete protease inliibitor cocktail 
Add to 50m] dHzO 
Storage buffer 50mM 2.5ml Tris/HCL 
(50ml) 15%w/v 6.25ml G]ycero](80%w/v) 
5niM 0.25 m] MgCl2( lM) 
1 tab Complete protease inhibitor cocktail 
Add to 50ml dHjO 
Tris /EDTA/BSA 250mM 12.5m] Tris/HCL(1M) 
buffer 
25 m M 2.5ml EDTA(0.5M) 
(50ml) 
15mg/nil 750mg Fatty-acid-free BSA 
Add to 50ml dHzO 
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2.1.3 Media 
Media Weight Compositions 
SD-ff lS-URA 20gm Glucose 
(IL) 1-Vg Yeast nitrogen base 
5g Ammonium sulphate 
0.7g Amino acid drop-out 
supplement -HIS-URA-TRP 
1ml Tryptophan (4mg/m]) 
20g Agar (added for solid media preparation) 
Add to 1000ml dHjO 
Y P G R (IL) 
Soli lOg Yeast extract 
20g Peptone 
800ml Galactose 
Sol II 40g Raffmose 
20g dHzO 
200ml 
S G R (IL) 
Soli 40g Galactose 
20g Raffmose 
900m] dHzO 
Sol II 3.5g Amino acid drop-out 
supplement -HIS-URA-TRP 
100ml dHzO 
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Media Weight Compositions 
S O C (IL) 20g Tryptone 
5g Yeast extract 
0.584g NaCl 
0.186g KCl 
2.003g MgClz 
2.465g MgS04 
3.6g Glucose 
HMI -9 (IL) 10.14g HMI-9 powder 
3.024g NaHC03 
14.3u] 2M P-mercaptoethanol 
10ml Penicillin/strepomycin 
10ml L-Glutamine 
100ml Foetal bovine serum 
to I L dHiO pH7.5 
L B (IL) lOg Tryptone 
5g Yeast extract 
lOg NaCl 
Add to lOOOml dHzO 
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2.1.4 Antibiotics 
Antibiotics Stock cone. Store temperature Final cone. 
Ampici l l in 
Doxycyclin 
Phleomycin 
G418 
50mg/ml 
Img/ml 
5mg/ml 
5mg/ml 
-20°C 
-20°C 
-20°C 
-20°C 
50^g/ml 
l^g /ml 
2.5^ig/ml 
2|ig/ml 
2.1.5 Strains and vectors 
Strains/ Vectors Work 
DH5a D N A cloning 
S. cerevisiae HIS-GAL A U R l Mutant yeast complemented by Z ftrwce/SLS 
r^jSLSlOOO 
Single Marker Bloodstream form Aureobasidin A efficacy and R N A i induction 
(SMB, T7RNAP::TETR::NEO) 
pRS426 Expression o f o f T Z J S L S in yeast 
p2T7 R N A i 
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2.2 Bioinformatic and ex vivo analyses 
2.2.1 T. brucei sequence analysis 
There are four T. brucei sphingolipid synthase (7Z7SLS) sequence orthologues evident 
in the T. brucei database (www.geneDB.org). Sequence alignments were performed 
using ClustalW (www.clustal.org). 77?09.211.1000 was analysed here. 
2.2.2 Metabolic labeling 
5. cerevisiae HIS-GAL A U R l 72>SLS]000 and controls were grown to exponential 
phase (ODaoo 0.5-0.7) and 10 units (OD6oo=l=l unit) of cells pelleted, resuspended in 
250|i] of SD-HIS-URA media and transferred into LoBind Eppendorf tubes. 5|il of 
5mM BSA-conjugated FL-ceramide and/or 50^Ci C'''ChoUne (GE Healthcare) was 
added and the cells were incubated with shaking at 30°C for 2 hours. The cells were 
washed with 1ml of dHiO and 400|il of choloroform:methanal (C:M; 1:1 v/v) added to 
the pellet before disruption with 0.1-0.2g of glass beads in a vortex mixer at fu l l speed 
for 10 seconds. 400^1 of CM.dHiO (C:M:W; 10:10:3 v/v/v) was added to the 
supernatant. The organic, lipid fraction was isolated by biphasic separation in a Folch 
wash, before being dried at 30°C in a rotary concentrator (Eppendorf 5301). The 
samples were then resuspended in 20ul of C:M:W, 10:10:3 and fractionated by HPTLC 
with C:M:0.25%KC1, 55:45:10 as the solvent phase. For 2-dimensional 
chromatography lipid extracts were fractionated in the first dimension with C:M:4.2M 
NH4OH (9:7:3) as the solvent phase and with C:M:Acetic Acid (45:30:7). 
Subsequently, the plates were scanned using a Fuji3000 fluorescent scanner and 
analyzed using A I D A Analyzer software (imaGenes). Radiolabelled samples were 
detected after spraying with ENTRANCE™ (DuPont) by exposure to BioMax (Kodak) 
f i lm. Bloodstream form T. brucei (SMB) were similarly labeled but with 10^ in 
28 
serum-free HMI-9 at 37°C, after a 1 hour incubation in the same media. Labeled 
mammalian, CHO cell controls were provided by Dr Steven Pratt. 
2.2.3 Mass spectromtery analyses of S. cerevisiae H I S - G A L A U R l 
TbSUSlOOO 
2 x l 0 ' freeze-dried yeast cells were extracted twice with 250ml of C:M:W, 4:8:3 in a 
sonicating water bath for 2 hours and centrifuged. The supematants were adjusted to 
C:M:V, 4:8:5.6, vortexed and centrifuged. The lower phase was loaded into nanospray 
tips (Micromass type F) and analysed by electrospray mass spectrometry (ES-MS and 
ES-MS-MS) using a Micromass Quattro Ultima triple quadrupole mass spectrometer 
in positive- and negative-ion modes. Capillary and cone voltages were 0.9 kV and 30 
V (negative ion) and 1.2 kV and 50 V (positive ion), respectively. Argon was used as 
the coUision gas (3.0x10'' Torr) to collect tandem spectra (ES-MSMS). Collision 
energies for parent ion scanning were: 60 V, negative-ion parents of m/z 241 for 
inositol-phospholipids; 37 V, positive-ion parents of m/z 184 for phosphate 
dylcholines. Collision energies for neutral-loss scanning were: 20 V, for neutral-loss 
m/z 141 scanning for phosphatidylethanolamines; 25 V, for neutral-loss m/z 181 for 
phospatidylserines. Negative-ion daughter ion spectra were collected with a collision 
energy of 60 V. 
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2.2.4 Agar diffusion assay 
Saccharomyces cerevisiae HIS-GAL A U R l complemented with TfcSLSlOOO (provided 
by Dr Paul Denny) were grown in SD-HIS-URA media overnight at 30°C. Cells were 
diluted into 80ml of SD-HIS-URA media so that ODm was approximately 0.2, and 
incubated until the ODeoo was 0.5-0.7 (exponential phase). 2.4x10^ cells 
(OD6oo=l=10^/ml cells) were pelleted in a benchtop centrifuge at 3000rpm for 5 
minutes. SD-HIS-URA solution I with 2% agarose and solution IT were warmed to 
45°C. 13.5ml solution I with 2% agarose and 1.5m] of SD-HIS-URA solution H were 
then mixed with the cell pellet and the mixture poured into square Petri dishes. When 
set inhibitors at appropriate concentrations in DMSO were applied and the plates then 
incubated at 30°C for three to four days. 
2.3 In vitro enzyme assay 
2.3.1 Preparation o f microsomes 
5L of cells, grown to exponential phase as above (2.3.1), were pelleted at 600Qrpm, 15 
minutes, 4°C and washed twice with ice-cold PBS. An equal volume of chilled glass 
beads and STE buffer were added to the pellet and the cells disrupted by vortex 
mixering. The mixture was centrifuged at 5000rpm, 10 minutes, 4°C and the 
supernatant transferred to a 50m] mbe. The pellet was re-extracted as before and then 
supematants combined and a microsomal fraction isolated by differential 
centrifugation: ]47000rpm, 35 minutes, 4°C in an SW60Ti rotor to remove the large 
granular fraction, followed by 35000rpm, 95 minutes, 4°C to pellet the small granular 
fraction containing microsomal membranes. The supernatant was removed and the 
microsomal membrane resuspended in 100^1 of storage buffer. The protein 
concentration was established using the Lowry method (Lowry et al, 1951), adjusted to 
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1 Omg/ml and the membranes were stored at -80°C until use. 
2.3.2 Preparation o f washed microsomes 
Equal volumes of the microsomal membrane preparation and a 2.5% CHAPS solution 
in STE were mixed together and incubated on the ice for 60 minutes. Subsequently the 
mixture was centrifuged at 43000rpm for 100 minutes at 4°C in a SW6OT1 rotor, the 
pellet resuspended in 50ul of storage buffer and stored at -80°C until required. 
2.3.3 In vitro rfcSLSlOOO assay 
5^1 of lOmM PI, 4^1 of 13mM PE or 4^1 of 13mM PC were added into LoBind tubes 
and air dried. 20\i\ of Tirs/EDTA/BSA buffer was added and the samples sonicated in a 
water bath for 2 minutes. 10|ig of unwashed (crude) or equivalent washed microsomes 
were added into each tube and the volume adjusted to 48^1 with dH20. 2)il of 5mM 
BSA conjugated BODIPY FL-ceramide were added in each tube and the reactions 
incubated at 30°C for 1 hour. 150^1 of C:M:W, 10:10:3 was added and, after 
centrifugation, the lower organic phase was removed to another LoBind mbe. The 
samples were subsequendy analysed by HPTLC as above. 
2.3.4 Optimum temperature fo r TbSLS activity in vitro 
20\il of Tris/EDTA/BSA buffer, IjjJ of 1 Omg/ml unwashed (crude) microsomes were 
added to LoBind Eppendorf tubes and dH20 were added to 48^1. These tubes were 
preincubated at 4°C, 20°C, 30°C, 33°C, 37°C and 40°C for 30 minutes, then 2|il of 
5mM BSA conjugated BODIPY FL-ceramide added and the reaction incubated at the 
appropriate temperature for another 1 hour. The samples were processed and analysed 
by HPTLC as above. 
31 
2.3.5 Efficacy of aureobasidin A against T^SLS activity in vitro 
20 \il o f Tris/EDTA/BSA buffer were added into Lobind Eppendork tubes. 5^1 o f 
different concentrations o f aureobasidin A were added together with 1 o f 1 Ogm/ml 
unwashed (crude) microsomes and dH20 to 48nl. The samples were preincubated at 
30°C for 30 minutes, then 2^1 o f 5mM FL-ceramide were added in each tube and the 
reaction incubated at the 30°C for another 1 hour. The samples were processed and 
analysed by HPTLC as above. 
2.4 Cellular analyses 
2.4.1 Parasite culture 
The bloodstream form T. bnicei strain Lister 427 engineered variant, Single Marker 
Bloodstream form (SMB, T7RNAP::TETR::NEO; Wirtz et al., 1999), was maintained 
in vitro at 37°C with 5% CO2 in H M I - 9 medium supplemented with 10% PCS and 
2.5^g/ml G418. 
2.4.2 R N A i 
Primers (SigmaGensys) were designed to amplify 2 fragments (approximately 180bps) 
completely conserved between the four copies o f 7Z?SLS. 
Primers Sequences 
5' 77) S L S R N A i 1 Xba l CATAGATCTAGAAAACTGTACCTTCTTeACCG 
3' rfe SLS R N A i 1 Xbal CATAGATCTAGAAGCAGGAGTGCGTATGATG 
5'7?> S L S R N A i 2 Xba l CATAGATCTAGAGGTTCCATACACTGTG 
3' SLS RNAi2 Xbal CATAGATCTAGACGAGAGGCAACGATGC 
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These primers were used to amplify the fragments from genomic T. brucei D N A (1 |ig) 
using FideliTaq (USB) according to manufacturer's protocols. 
Engineered to contain 5' and 3' Xbal sites these 2 fragments were subsequendy 
digested using Xbal (Promega) and ligated using T4 ligase (Promega) into the p2T7 
RNAi vector before selection in DH5a Escherichia coli. 
A Tb]JCB2 (SPT subunit 2) fragment cloned into p2T7 was provided by Dr F Denny. 
p2T7 constructs were amplified in E.coli and isolated by Midi Prep (Qiagen) before 
being linearized by NotI digestion, at least lOpg of DNA was used for each 
transfection. 2.5x10' cells were grown for each transfection and pelleted at lOOOrpm, 
1 Ominutes at room temperature in a benchtop centrifuge. Cells were washed with 25ml 
of cytomix, then resuspended in the same at 6xl0^/ml). lOpg of linear plasmid in lOpg 
was mixed with 450nl of cells in an Eppendorf tubes, transferred into 2mm gap 
elecu-oporation cuvettes (Sigma) and pulsed at 1.4kV, 2.5)iF in a BioRad Gene Pulser 
n. After electroporation, cells were transferred into 36ml of HMI-9 media and 
incubated at 37°C, 6 hours before adding 7.2|il of 5mg/ml G418 and ISjil of 5mg/ml 
phleomycin. Parasites were transferred into 24 well plates widi each well containing 
1ml of cells. Plates were incubated at 37°C for approximately six days and the selected 
transfectants sub-cultured. 
Two flasks of RNAi transfected SMB cells were grown in HMI-9 with 2.5n/ml 
phleomycin and 2.5ng/ml G418 with an initial cell density of IxlO^/ml. l | ig /ml of 
doxycyclin was added into one flask, the other acted as a control. Parasites were 
incubated at 37°C and cell counts and observations made after 24, 48 and 72 hours. 
Cells were sub-cultured to IxlO^/ml when diey reached or exceeded 2xl0*/ml. 
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RNA was extracted fi-om approximately 10^ parasites using the RNeasy kit (Promega) 
as per the manufacturer's protocol except that that cells were disrupted using glass 
beads in 600^1 o f RTL buffer prior to extraction. Isolated RNA was treated with 
DNasel (Promega) at 37°C, 30 minutes before 3fig was used to make cDNA using the 
3' primers above and Superscript I I (Promega) according to the manufacturer's 
protocols. Subsequently, the primers below were used to amplify cDNA fi-agments 
using PCR Master M i x (Promega) and the products then analyzed by agarose gel 
electrophoresis. 
2.4.3 Aureobasidin A efficacy against T. brucei 
T. brucei SMB were cultured in the presence o f various concentrations o f aureobasidin 
A. Growth was analyzed at 24 hour intervals as below. 
Primers Sequences 
5' TbSLS AAACTGTACCTTCACCG 
3' TbSLS AGCAGGAGTGCGTATGATG 
5' TbQTlJB GGAGCGCATCAATGTGTAC 
3 'Tb6TUB CAGGCAGCAGGTGACGCCG 
5' Tb LCB2 ATGCCTACTTACGTGGAGGC 
3' TbLCBl CGTCGAAACCCGCTCCATCAC 
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Chapter 3: Results 
3.1 General information 
African sleeping sickness which is listed as a tropical disease research (TDR) category 
1 disease is emerging as a serious problem in parts of sub-Saharan Africa and new 
drugs are urgently needed (www.who.int/tdr/). According to the 2004 WHO report, 
48000 people lost their lives to this disease in that year. Compared to humans and other 
mammals, pathogenic protozoa and fungi have differences in their sphingolipid 
biosynthetic pathways. This difference offers target sites for novel inhibitor molecules 
and the opportunity for developing new drugs (Heung et al., 2006). 
This report describes experimental work comprising 3 parts. 
1. Funcdonal identification and characterization of the Trypanosoma brucei 
sphingolipid synthase (71?SLS). 
2. The inhibition of T. brucei sphingolipid synthase using a known anti-fungal drug 
aureobasidin A. 
3. Functional analysis using RNA interference (RNAi). 
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3.2 Identification and characterisation of the T. brucei sphingolipid 
synthase 
3.2.1 T. brucei sphingolipid synthase (rfcSLS) complements an A U R l mutant 
yeast 
Four gene sequences (77709211.1000, ™9.211 .1010 , 72>09.211.1020 and 
7609.211.1030) were previously identified in the genome database (www.genedb.org) 
as sequence orthologues of the inositol phosphorylceramide synthase (LwIPCS) from 
the related kinetoplastid Leishmania parasite (Denny et al., 2006). Further analysis of 
the genomic sequence identified the complete open reading frames (ORFs) found on 
chromosome 9 which are predicted to encode 4 transmembrane proteins with more 
than 70% identity. Most variation occurs at the carboxy-termini, a region predicted to 
lie on the cytosolic side of the membrane away from the active site at the Golgi lumen 
(Denny et al., 2006, figure 3.1). Like LmlPCS, TbSLS possesses conserved 
sphingomyelin (SM) synthase domains: D l , D3 and D4 (Huitemia et al., 2004). D3 
(C-G-D-Xj-S-G-H-T) and D4 (H-Y-T-A:-D-V-XrY-X6-F-X2-Y-H) are similar to the C2 
and C3 motifs in Lipid-Phosphate Phosphatase (LPP, Neuwald, 1997) and domains 3 
and 4 of the fungal AURlp (Heidler and Radding, 2000). D3 and D4 contain the 
histidine and aspartate residues (underlined) that form the catalytic triad which 
mediates nucleophilic attack on hpid phosphate ester bonds (Huitema et al., 2004; 
Neuwald, 1997). Gene mutation at this triad inhibits both the fungal and Leishmania 
IPC synthase (Levine et al., 2000; Mina and Denny, personal communication). One of 
the predicted T. brucei sphingolipid synthase isoforms, the longest (77709.211.1000, 
777SLS1000), was analysed in this study. 
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Figure 3.1: 
Predicted protein sequences of the 4 T. brucei ORFs aligned using ClustalW 
1.81 (http://www.ebi.ac.uk/Tools/clustalw2/index.html). The blue regions 
indicate the non-identical regions. TM - predicted transmembrane domains 
(Denny et al., 2006); D l , D3 and D4 - conserved SM synthase domains. 
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The auxotrophic mutant Saccharomyces cerevisiae strain YPH499-HIS-GAL-AUR1 in 
which the essential A U R l IPC synthase gene is under the control of a galactose 
inducible promoter is unable to grow in the absence of galactose. However, this can be 
rescued by the expression of ZTMIPCS (Denny et al., 2006). Similarly, TbSLSlOOG 
expression complemented the mutant cell indicating that 77>SLS1000 is a functional 
orthologue of the yeast AUR1 gene. 
3.2.2 Functional identification of T. brucei S L S 
To understand die function of TfeSLSlOOO, the complemented yeast and pathogenic 
bloodstream (BSF) T. brucei were labeled with fluorescent BODIPY F L Cs-ceramide 
(a substrate for sphingolipid synthases) complexed with BSA as described in the 
Materials and Methods. The lipids were extracted and analysed by the high 
performance thin layer chromatography (HPTLC). S. cerevisiae which produces IPC 
via the action of IPC synthase (Becker and Lester., 1980) and mammalian Chinese 
Hamster Ovary (CHO) cells which produce sphingomyelin (SM) via the action of SM 
synthase (Huitema et al., 2004) were similarly labeled and their products used as 
makers (figure3.2). The B S F parasites produce 2 labeled products: one that 
co-migrated with SM (X) and another (Y) which migrated beyond IPC. The 
complemented yeast produced 2 apparently similar species that co-migrated with the 
BSF products, as well as a faint band that co-migrated with IPC (figure 3.2). These 
data indicated that TT^SLSIOOO functions primarily as a SM synthase. 
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Figure 3.2: 
Metabolic labelling. TbSLSlOOO, S. cerevisiae and mammalian cells (CHO) 
were labelled with BODIPY FL-ceramide. Samples were analysed by HPTLC. 
CER - ceramide; Y - unknown; 
IPC - inositol phosphorylceramide; 
SM - sphingomyelin; O - origin; 
BSF Tb - bloodstream form T. brucei; CHO -Chinese Hamster Overy cells; 
HIS-GAL-AURl TbSLS - auxotrophic mutant yeast complemented with 
TbSLSlOOO 
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3.2.3 2-diniensional H P T L C analyses 
In order to further characterize the labeled sphingolipids extracted from the 
T T j S L S I O O O complemented yeast and the T. brucei bloodstream form parasites, 
2D-HPTLC was used to further separate the different ceramide-labeled species 
produced. 2 labeled lipid fractions were loaded at the same origin on a HPTLC plate 
and separated in 2 dimensions using 2 different solvent systems. 
As shown in figure 3.3, the lipids from the 72>SLS1000 complemented yeast and T. 
brucei BSF cells separated into three groups: apparent IPC (only produced by the 
complemented yeast), and unknowns X (shown to co-migrate with SM above), and Y. 
This indicated that the X and Y are produced in bodi T. brucei B S F cells and the 
complemented yeast; therefore, it seems that TbSLSlOOO (and, presumably, its 
isoforms) functions as the major sphingolipid synthase in the pathogenic form of T. 
brucei. IPC could only be detected in die complemented yeast (see above). Notably, 
this lipid has only been detected in insect stage, procyclic form T. brucei (Giither et al., 
2006). 
In one dimensional HPTLC, unknown X co-migrated with SM (see above). To further 
investigate the identity of X, labeled lipids from T. brucei BSF parasites and 
mammalian cells were analyzed by 2D-HPTLC. As seen in figure 3.4, SM and X could 
not be separated under these conditions. This supported the suggestion that X is SM 
and that 727SLS1000 functions primarily as a SM syndiase. 
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UnknoMm X 
Figure 3.3: 
2 D HPTLC analysis. T. brucei SLS complemented yeast and T. brucei BSF 
parasites were labeled with BODIPY FL-ceramide and the lipids extracted and 
analysed by HPTLC. The samples were spotted at the same labeled origin and 
separated in 2 dimensions using 2 different solvent systems. IPC- Inositol 
phosphorylceramide 
Ceramide 
Unknown Y 
Unknown X/SM 
Figure 3.4: 
2 D HPTLC analysis. T. brucei BSF parasites and mammalian CHO cells were 
labeled with BODIPY FL-ceramide and the lipids extracted and analysed by 
HPTLC. The samples were spotted at the same labeled origin and separated in 
2 dimensions using 2 different solvent systems. GSL - glycosphingolipid; SM-
sphingomyelin. 
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In order to prove that rZ)SLS1000 fiinctions as SM synthase, complemented yeast were 
labeled with C choline and BODIPY FL-ceramide as described in Materials and 
Methods. The formation of SM via SM synthase requires phosphatidylcholine (PC) as 
the donor substrate (Huitema et al., 2004) and since ''^ C choline is incorporated into PC, 
radio isotope will also label any SM produced by the complemented yeast. 
Figure 3.5 shows the result of this dual labeling when the lipids are separated by 
2D-HPTLC. It is clear to see PC labeled on the plate; however, no '''C choline species 
were co-labeled with ceramide. This indicated that SM synthase activity is absent, X is 
not SM and that TbSLSlOOO complemented yeast do not produce SM. 
Figure 3.5: 
2D HPTLC analysis. TbSLS 1000- complemented cells were labeled with C 
choline (black) and BODIPY FL-ceramide (white). 
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Figure 3.6: 
Negative ion mass spectra of lipids from 7Z)SLS1000 and 5cAURl 
complemented mutant yeast. 
Moreover, lipids extracted from TZ^SLSIOOO were analysed by mass spectrometry 
(with Mike Ferguson, Unversity of Dundee); 3 major complex sphingolipids were 
visualized in the negative ion spectrum at mass 952.7 (44:0,4), 968.7 (44:0,5) and 
980.7 (46:0,4), all of these represent IPC species (figure 3.6). No SM or ethanolamine 
phosphorylceramide were detected (positive ion spectrum; data not shown). 
Comparing the mass specfrometry results of T^JSLSIOOO and 5cAURl complemented 
yeast, showed no differences between the 2 cell lines. This indicated that 7?JSLS1000 
fimctions as an IPC synthase rather than SM synthase. However, this method did not 
identify the unknown X and Y species. 
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3.2.4 in vitro assay of r^jSLSlOOO 
In order to further understand the activity of T. brucei sphingolipid synthase, an in vitro 
assay was established as described in Materials and Methods. Microsomal membranes 
prepared from the 77?SLS1000 complemented yeast were treated with 
phosphatidylinositol (PI), phosphatidylethanolamine (PE) or phosphatidylcholine (PC) 
as donor substrates and BODIPY FL-ceramide as the receptor substrate. 
Subsequently, the lipids were extracted and analyzed by H P T L C plate as previously. 
The addition of the donor substrate had no demonstrable effect on the high level of 
activity observed in the microsomes (data not shown). This might be due to the high 
level of donor substrate present in the microsomal membranes. In addition, when 
compared to metabolic labeUng, less unknown Y was synthesized with respect to IPC 
in this assay. 
Therefore, to reduce substrate contamination the microsomal membrane fractions were 
washed with 2.5% 3-[3-(cholamidopropyl) dimethylammonioj-l-propane sulfonate 
(CHAPS) to eliminate most of the endogenous lipids and proteins (Aeed et al., 2004, 
Mina and Denny, personal communication). 
Without the addition of donor substrate, and when compared with a crude preparation, 
the CHAPS-washed membranes showed a relatively low level of TfeSLSlOOO activity 
as determined by the synthesis of unknowns X (figure 3.7). On the addition of 
exogenous substrate (bovine PI, P E or PC), only the sample which treated with PI 
showed an increase in sphingolipid synthase activity, as evidenced by the production of 
IPC. In contrast, equivalent experiments with S. cerevisiae, demonstrated diat the yeast 
IPC synthase cannot use mammalian or plant PI. (Mina and Denny, personal 
communication) There was no difference in the formation of X or Y after adding 
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bovine PI in the TdSLSlOOO assay. 
These results demonstrated that rZ»SLS1000 functions as an IPC synthase indicating 
that cells produce IPC via IPC synthase. The identities of X and Y, products of both T. 
brucei BSF and 37)SLS1000 complemented yeast, are still unknown. However, it is 
assumed that they are the result of IPC synthase activity in T. brucei BSF cells. 
TbSLSlOOO PI PE PC 
Figure 3.7: 
In vitro assay of JZ^SLSIOOO. 7?)SLS1000 - unwashed microsomal fraction 
assayed with with BODIPY FL-ceramide as the receptor substrate and without 
exogenous donor substrate. CHAPS-washed microsomal fractions assayed with 
BODIPY FL-ceramide and either no exogenous donor substrate (-) or 
phosphatidylinositol (PI), phosphatidylethanolamine (PE) or 
phosphatidylcholine (PC). 
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3.2.5 Affect of temperature on T/JSLSIOOO IPC synthase activity 
In order to observe the effects of temperature on the 77>SLS1000, unwashed 
microsomes were incubated with BODIPY FL-ceramide (endogenous donor substrate 
acted as donor) at various temperatures (4°C, 20°C, 2 6 ^ , 3 0 r , 3 3 ^ , 37°C and 40^0). 
As seen in figure3.8, the activity of TfeSLSlOOO, as determined by the production of 
unknown X and IPC showed the lowest activity at 4°C and the highest activity at 40°C. 
Similarly, the T. cruzi IPC synthase activity had the lowest activity at 4°C, however the 
highest activity was observed at 37°C (Figueiredo et al., 2005). Patients infected by T. 
brucei usually have an acute disease with an accompanying high fever (Barret et al., 
2003). In contrast, T. cruzi produce a chronic infection in tissues including cardiac 
system, digestive system and CSF without a significant fever (Barret et al., 2003). 
Additionally, this disease is transmitted by sand flies whose temperature reflects their 
tropical and sub-tropical habitat. 
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Figure 3.8: 
Temperature assay. The established in vitro assay was performed at 4, 20, 26, 
30, 33, 37 and 40°C and activity determined by the accumulation of products 
unknown X and inositol phosphorylceramide (IPC). 
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3.3 Aureobasidin A inhibition of JASLSIOOO 
3.3.1 Agar diffusion assay 
IPC synthesis a recognized target for anti-fungal drugs and aureobasidin A is widely 
utilized experimental inhibitor (Sugimoto et al., 2004). Aureobasidin A inhibits 
Leishmania ZmlPCS activity (Deimy et al. 2006; Mina and Denny, personal 
communication), therefore, it was investigated whether this drug affected the L/wlPCS 
orthologue, HJSLSIOOO. Using the complemented yeast in an agar diffusion assay as 
described in Materials and Methods it was shown that TftSLSlOOO is sensitive to 
aureobasidin A at both 25 and 100 | iM. This demonstrated that the enzyme is more 
susceptible to the inhibitor than LmlPCS which is only sensitive to lOO^M 
aureobasidin A (Denny et al., 2006). Cycloheximide (which inhibits protein translation) 
and myriocin (which inhibits serine palmitoyltransferase, an enzyme involved in the 
first step of sphingolipid synthesis) were used in the assay as positive controls. 
lOOuM 
AbA 
DMSO 
Figure 3.9: 
Agar diffusion assay. T^SLSIOOO complemented yeast were grown in 
SD-HIS-URA agar and 1, 2 or 3^1 of 25 ]M cycloheximide (CYC), 1 mM 
myriocin (MYR) and 25 ^ M or 100 |^M of aureobasidin A (AbA) were dropped 
on to the plate. DMSO was used as a negative control. 
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3.3.2 in vitro assay of TbSLS aureobasidin A sensitivity 
Having established that TdSLSlOOO is sensitive to aureobasidin A., unwashed 
JZJSLSIOOO microsomal membranes were pretreated with 0-25nM of this drug and 
labeled with FL-ceramide. The lipids extracted fractionated by HPTLC and quantified 
to facilitate calculation of the IC50 of aureobasidin A.. 
Figure 3.10 shows that the synthesis of IPC was strongly inhibited by a 25nM 
contentration of aureobasidin A. In contrast, the production of unknown X was less 
sensitive to the inhibitor. The IC50 with respect to IPC synthase activity was calculated 
as approximately 15nM aureobasidin A. This contrasts with a values for the S. 
cerevisiae enzyme of 0.2nM (Nagiec et al., 1997). 
IPC 
Unknown X 
0 5 10 15 20 
Concentration of aureobasidin A (nM) 
Figure 3.10: 
The inhibitory effects of aureobasidin A in an in vitro assay of T/bSLSlOOO 
activity. 0 to 20nM of aureobasidin A was added to each sample before the 
addifion of BODIPY FL-ceramide. 
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3.3.3 Cell based assay of aureobasidin A sensitivity 
It has been shown that aureobasidin A inhibits TbSLS in the complemented yeast cell 
line and in vitro. However, what is the effect of aureobasidin AonT. brucei BSF cells? 
To answer this question, the drug was added directly to the culture media at various 
concentrations and the cell growth assessed every 24 hours for 3 days. 
As seen in figure3.11, when the concentration of aureobasidin A was 5 )ag/ ^il or more, 
cell growth was completely inhibited and the parasites were dead within 24 hours 
(assessed by observing motility). The IC50 of T. brucei BSF cells was less than 1 |xg/|xl 
or 0.9mM aureobasidin A (figure 3.11). 
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Figure 3.11: 
T. brucei BSF cell growth curve. Aureobasidin A at 0 to 5 ^g/^ll was added to 
the growth media. A: 0-5ng/ nl. B: 2-5|ag/ nl. 
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In order to analyze the effect of aureobasidin A on sphingolipids synthase, T. brucei 
BSF parasites were treated with aureobasidin A between 0 and 4ng/|Al and incubated at 
37°C for 2 hours (before the cells started dying) and the parasites were labeled with 
BODIPY FL-ceramide. The lipids were extracted and fractionated by HPTLC (figure 
3.12). The activity of J&SLS, determined by the synthesis of both unknowns X and Y, 
decreased with increasing concentrations of aureobasidin A which suggested that 
inhibition of TfeSLS by aureobasidin A leads to the death of T. brucei BSF cells. 
OHg/|il 2ug/ | i l 3ng/ i i l 4ng /n l 
• 
Unknown Y 
Unknown X 
Figure 3.12: 
Metabolic labelling of T. brucei BSF parasites with BODIPY FL-ceramide in 
the presence of 0-4 |i.g/|J.l of aureobasidin A. 
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3.4 RNAi 
3.4.1 R N A i constructs 
Three RNAi constructs were formed in the p2T7 vector, which is designed to produce 
double stranded RNA from head-to-head T7 promoters when induced by tetracycline 
(LaCount et al. 2000), and used to inhibit the expression of T. brucei genes involved in 
sphingohpid biosynthesis. The first of these was 72>-LCB2 (Tfol0.70.3220) which 
encodes part of the SPT, the first enzyme in sphingolipid synthesis. 
The other 2 constructs were based on sequence common to all 4 TliSLS isoforms 
(77>09.211.1000, 1010, 1020 and 1030): TT^SLS RNAil and T T j S L S RNAi2. These 
constructs were linearised and transfected into SMB (Single Marker Bloodstream-form) 
T. brucei (Wirtz et al., 1999) which were dien selected with phleomycin. 
3.4.2 Tb-UCm R N A i 
Non-transfected SMB cells were treated with doxycyclin as a control. Doxycyclin is a 
tetracychne derivative which is used to induce the production of RNAi. As can be seen 
in figure 3.13, the SMB ceUs grew normally in the presence of doxycyclin, this 
indicates that the antibiotic has no toxic affect. 
However, on the induction of 72>-LCB2 RNAi the growth rate became decreased 
markedly and cell death was apparent (by light microscopy). This indicated that 
sphingolipid biosynthesis is essential for the proliferation of T. brucei BSFs. After 
subculturing the cells twice, the growth rate of the induced cells was equivalent to that 
of the non-induced cells, indicating that parasites resistant to RNAi had been selected 
(figure 3.14). 
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Figure 3.13: 
Growth curve o f control SMB parasites with and without doxycyclin. 
•-doxy 
•+doxv 
4 
Days 
Figure 3.14: 
Growth curve o f transfected LCB2 R N A i cells induced by doxycyclin. 
Parasites were subcultured to Ix loVml when non-induced cells reached or 
exceeded 2x1 oVml. 
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In order to confirm that this phenomenon was due to the specific suppression o f the 
target gene by R N A i , R N A was extracted fi-om the cells after 2 days o f inducfion and 
analyzed by RT-PCR. Tb-LCB2 mRNA was clearly decreased after 48 hours induction, 
whereas control- a-tubulin mRNA was unaffected. This indicated that the R N A i 
response was gene specific. 
A. 
5 0 0 b p -
B. 
600bp-
Figure 3.15: 
RT-PCR o f T : brucei LCB2RNAi cells. 
A. LCB2 mRNA fragment (~480bp), B . a-tubulin mRNA fragment (~580bp), 
—: without doxycyclin, +: with doxycyclin for 48 hours 
3.4.3 TbSLS R N A i 
R N A i constructs, TbSLS R N A i l and TbSLS RNAi2 , were fransfected into T. brucei 
SMB cells. However, only TZJSLS RNAi2 allowed selection o f viable parasites. 
Non-induced J&SLS RNAi2 cells grew in a similar manner to the parental SMB 
parasites. In contrast, the induced parasites grew very slowly with significant cell death 
(by light microscopy). Just like 7?)LCB2 R N A i , the growth rate o f induced cells was 
equivalent to that o f non-induced cells after subculturing the cells twice (figure 3.16). 
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Figure 3.16: 
Growth curve o f transfected 7Z?SLS R N A i cells induced by doxycyclin. 
Parasites were subcultured to 1 x 10^/ml when non-induced cells reached or 
exceeded 2x10*/ml. 
Aga in , RT-PCR was used to confirm the specificity o f the R N A i . As shown in figure 
3.17, TbSLS m R N A was significantly decreased after 48 hours inducfion. Control 
a-tubulin mRNA was unaffected. 
TbSLS Tubulin T u b u l i n - R T 
- + - + - + 
B O O b p -
Figure 3.17: 
RT-PCR o f Z brucei SLS R N A i cells. 
A. TbSLS m R N A fragment (~400bp), 
B. B. a-tubulin m R N A fragment (~580bp), 
—: without doxycyclin, +: wi th doxycyclin for 48 hours 
Negative control is tubulin RT-PCR without RT 
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To directly ascertain the affect of TbSLS RNAi2, induced and non-induced cells were 
grown for 3 days. After that, cells were labeled with BODIPY FL-ceramide and 
analysed as described previously. After induction, the 7??SLS RNAi2 transfected cells 
produced 38% less of X than non-induced cells. However, there was no difference in 
the quality of Y (data not shown). The reason of diis is still unknown. 
A l l of these data confirm that sphingolipid synthesis is essential for the proliferation of 
BSF and procyclic T. brucei (Sutterwala et al., 2007; Fridberg et al., 2008). They also 
demonstrated that the T. brucei sphingolipids synthase (72iSLS) is an essential activity 
in the parasite and a valid drug target. 
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Chapter 4: 
Discussion 
Chapter 4: Discussion 
4.1 Identification of the T. brucei sphingolipid synthase 
In recent years, it has become clear that sphingolipid synthase represents a promising 
drug target for many parasitic diseases, such as those caused by T. cruzi and L. major 
(Heung et al., 2006). However, the biochemical function of the T. brucei sphingolipid 
synthase remained unknown (Denny et al., 2006). To begin to understand the role of 
this enzyme in pathogenesis, bloodstream form cells were labeled with the fluorescent 
substrate- FL-ceramide and lipids extracted and analyzed by HPTLC. 
Two species of complex sphingolipid were synthesized and evident on the plate: SM 
(X) and Y (figure 3.2). Comparing the Rf values, under the conditions employed, of 
labeled T. brucei sphingolipid species with similarly labeled 5. cerevisiae (which 
synthesize IPC via IPC synthase, Becker and Lester, 1980) and CHO cells (which 
produce SM via SM synthase, Huitema et al., 2004), X (0.45) migrated with SM (0.45) 
and Y(0.78) migrated further than IPC (0.74). 
To analyse the T. brucei sphingolipid synthase, one of the four coding sequences in 
genome database (www.genedb.org), 77709.211.1000 (TT^SLS 1000), was cloned into 
the yeast expression vector pRS426MET25 subsequently transformed into 
YPH499-HIS-GAL-AUR1 S. cerevisiae mutant yeast in which the essential A U R l , the 
ETC synthase is regulated by G A L l promoter and so repressed in the presence of 
glucose (Denny et al., 2006). 72?SLS1000 complemented the auxotrophic mutant yeast 
and metabolic labeUng with FL-ceramide and analyses of these and T. brucei 
bloodstream form cells found that whilst the parasite produced X and Y, the 
complemented yeast produced lipids that co-migrated with X , Y and IPC (figure 3.2). 
To identify X and Y, 72>SLS1000 complemented yeast were labeled with C"* choline 
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which would be incorporated into SM and analyzed by 2D-HPTLC, in addition mass 
spectrometry was employed. These experiments failed to identify X or Y, however, 
mass spectrometry confirmed the presence of IPC. This indicated that 72>SLS functions 
primarily as an IPC synthase in this axenic system. 
To analyse the T. brucei sphingolipid synthase activity in vitro, detergent-washed 
72>SLS1000 complemented yeast microsomal fractions were treated with FL-ceramide 
as acceptor substrate and PI, PE or PC as donor substrates for IPC, EPC and S M 
synthesis respectively. The result shown in figure 3.7 demonstrated that the sample 
treated with PI significantly increased the synthesis of IPC. PE and PC did not function 
as substrates. This confirmed that 77?SLS 1000 functions as an IPC synthase. 
Furthermore, the microsomal membranes were reacted at different temperatures to 
observe the variation of sphingolipid synthase activity. As seen in figure3.6, 
TTJSLSIOOO had highest activity at 40°C, whilst T. cruzi sphingolipid synthase has 
highest activity at 37°C (Figueiredo et al., 2005) and the L major enzyme at 30°C (J-
Mina, personal communication). Unlike L major, which causes dermal lesions where 
the temperature is near 30-33°C (http://www.who.int/leishmaniasis/en/), or T. cruzi, 
which leads in chronic disease of cardiac tissue, patients infected by T. brucei usually 
have an acute disease with an accompanying high fever (Barret et al., 2003). These 
results reflect the different pathogenic lifestyle of these parasites. Therefore, the 
different optimal operating temperatures of these orthologues may reflect the different 
pathogenic lifestyle of these parasites. 
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4.2 Inhibition of T. brucei SLS by aureobasidin A 
Having established that TbSLS 1000 functions as an IPC synthase, subsequent studies 
focused on the inhibition of this activity. Aureobasidin A (AbA), which is non-toxic to 
animals, has been used as a specific, experimental anti-fungal to inhibit IPC synthase 
in yeast species, such as 5. cerevsiae and Candida (Zhong et al., 2000). Experiments 
have also demonstrated that AbA inhibits IPC synthase in the kinetoplastid parasites T. 
cruzi and L. major. (Figueiredo et al., 2005, Denny et al., 2006) 
To establish whether AbA inhibits the T. brucei sphingolipids synthase, TbSLSlOOO 
complemented yeast were assayed for their susceptibility to diis inhibitor in an agar 
diffusion assay. Cells growth was inhibited by 25^M and 100|iM AbA indicating that T. 
brucei sphingolipid synthase is susceptible to AbA. Previously, LmlPCS complemented 
yeast were shown to only be susceptible to the higher concentration of AbA (Denny et 
al., 2006). Metabolic labeling with FL-ceramide demonstrated that the synthesis of 
labeled X and IPC decreased with increasing the concentrations of AbA and Y was 
barely detectable after treatment. The activity of 777SLS1000 (as defined by the 
synthesis of X, Y and IPC) was totally inhibited when the cells were treated with more 
than 25nM AbA. The IC50 widi respect to IPC synthase activity was calculated as 
approximately 15nM AbA demonstrating diat T&SLSIOOO activity is very sensitive to 
this inhibitor. 
Despite these in vitro analyses the efficacy of Ab A with respect T. brucei remained 
unknown. To begin to understand the effect of this drug on pathogenic bloodstream 
form T. brucei, 0-5|ig/|J.l of AbA was added to cells and the parasites observed by light 
microscopy every 24 hours. As expected, the parasites grew more slowly and died in 
the presence of AbA. 
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To verify the effect of AbA inhibition on the parasites, T. brucei bloodstream form cells 
were labeled with FL-ceramide and lipids extracted to analyze the variation of TbSLS 
activity after treated with AbA 2 hours. Notably, the quantities of X and Y decreased 
which indicated that the inhibition of the enzyme by AbA lead to growth inhibition and 
death of T. brucei bloodstream form parasites. 
4.3 Inhibition of 7: brucei SLS by RNAi 
Following the chemical inhibition of TbSLS, RNAi of all 4 isoforms simultaneously 
was also used to genetically inhibit the function of the T. brucei enzyme. 
On induction of RNAi , parasites ceased to grow and many were scored as dead by 
light microscopy. RT-PCR confirmed that this was attributable to the specific 
down-regulation of TbSLS mRNA. As expected, RNAi was TTJSLS lead to a reduction 
in induced cells produc tion of sphingolipid X compared with controls after 
FL-ceramide labeling. However, not much difference in the production of enzyme 
product Y. Given that the target gene was not fully suppressed is the residual activity 
maybe due to extant enzyme activity. 
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4.4 Conclusion 
We have demonstrated that the T. brucei sphingolipid synthase functions as an IPC 
synthase. Furthermore, this enzyme is shown both chemically and genetically to be 
essential for T. brucei bloodstream form growth, validating TbSLS as a drug target in 
the pathogenic stages of this parasite. 
However, since only one of the 4 TbSLS coding sequences (7l>09.211.1000) was 
amplified and analysed in this study, it wi l l be necessary to analyse the other 3 closely 
related isoforms to identify any differences. 
Moreover, the mechanism of T. brucei sphingolipid synthase activity is still unclear. T. 
brucei bloodstream form cells produce X and Y rather than IPC as would be expected 
from the analysis here. Further analysis to identify sphingolipids X and Y is necessary 
to ful ly understand the function of T. brucei sphingolipid sythase. 
Ultimately it is hoped that these studies may lead to the development of a new drug 
leads and, subsequently, to therapies. Such drugs are much needed due to the toxicity 
of current treatments for African sleeping sickness and because of the rise drug 
resistance was found in this disease. (Maser et al., 2003) 
4.5 Future work 
It remains necessary to identify the unknown sphingolipids X and Y. Recent work has 
demonstrated that X is sensitive to SMase, indicating that it is SM (Pan et al, 
submitted). However, mass spjectrometry failed to identify SM (or other non-inositol 
sphingolipids, i.e. Y ) in extracts of complemented yeast. An alternative approach 
would be to use this technique to directly detect labeled products as previously 
described (Landoni et al, 2008). This could be performed on labeled microsomal 
samples or metabolically-labeled yeast. 
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The experiments described in this report were focused on in vitro studies. Subsequent 
research wil l need to focus on the the function of T. brucei SLS in vivo. To facilitate 
this, the established mouse animal model would be utilized. Mice would be infected 
with bloodstream form RNAi transfected parasites by intra-peritoneal innoculation. 
Half of the infected mice would be given water containing doxycycline (which wi l l 
induce RNAi in the T. brucei) and the survival rate of these mice, compared with 
controls, established (Lecordior et al., 2005). In addition, the efficacy of AbA in 
infected animals is unknown, although this drug has previously been show to be 
effective against systemic Candida albicans in a mouse model when given both orally 
and sub-cutaneously (Takesako et al, 1993). Similar experiments with mice infected 
with T. brucei as above could establish the efficicacy of AbA against an animal model 
of African Sleeping Sickness (Yabu et al., 2003). 
The primary future objective must be the discovery of more lead inhibitors of T. brucei 
SLS. The development of an in vitro microtitre plate-based assay in the laboratory 
makes high throughput screening against this enzyme activity a possibility (Mina et al, 
2009). This may identify compounds which could then further chemically modified to 
increase efficacy before being tested m vitro and in vivo, as discussed above, against 
the laboratory isolate used here and against field isolates to confirm effectiveness. 
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Abstract 
Sphingolipids are important components of eukaryotic membranes, particularly the 
plasma membrane, and are involved in a diverse array of signal transduction processes. 
In the Eukaryota the biosynthetic pathway for the formation of these lipid species is 
largely conserved. However, several pathogenic fungi and protozoa synthesize inositol 
phosphorylceramide (IPC) as the primary phosphosphingolipid rather than 
sphingomyelin (SM) as do mammals. This process is catalyzed by the enzyme IPC 
synthase, a recognized target for anti-fungals encoded by the AURl gene in yeast. 
Recently functional orthologues of die A U R l p have been identified in a group of 
insect vector-borne pathogenic protozoa, the Kinetoplastida, which are responsible for 
a range of so-called neglected diseases. Of these the Trypanosoma brucei species are 
the causative agents of Human African Sleeping Sickness in many of the most 
underdeveloped regions of Africa. The available treatments for these diseases are 
limited, of decreasing efficacy, and often demonstrate severe side-effects. Against this 
background the T. brucei sphingolipid synthase, an orthologue of the yeast AURlp , 
may represent a promising target for novel anti-protozoals. Our studies identify this 
protein as a novel bifunctional enzyme capable of catalysing the synthesis of both IPC 
and SM, both known to be present in the parasite. Furthermore, the synthase is 
essential for parasite growth and can be inhibited by a known anti-fiingal at 
sub-nanomolar levels in vitro. Most notably this drug demonstrates trypanocidal 
activity against cultured bloodstream form parasites. Thus T. brucei sphingolipid 
synthase represents a valid and promising drug target. 
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Introduction 
Trypanosoma brucei species are protozoan parasites of the order Kinetoplastidae and 
the etiological agents of both Human African Trypanomiasis (HAT), otherwise known 
as sleeping sickness, and diseases of economically important animals (e.g. nagana in 
cattle) (1). These diseases are endemic in much of sub-Saharan Africa, with H A T 
causing a burden of approximately 1.6 million disability adjusted life years 
(http://www.who.int/tdr/). This distribution across some of the most under developed 
regions of the world is coupled with a paucity of effective therapies with those 
available being either too expensive (e.g. eflomithine) or exhibiting catastrophic 
side-effects (e.g. melarsoprol). Together with the leishmaniasis (caused by the related 
Leishmania species), H A T is described by die World Health Organization as a 
Category I - Emerging or uncontrolled disease (http://www.who.int/tdr/). This 
categorization emphasizes the importance of the discovery of new drug targets and 
anti-HAT compounds to combat a disease which causes in excess of 50 0(K) deaths per 
annum (25). 
Sphingolipids are a diverse group of amphipathic lipids tiiat perform essential 
functions in eukaryotes. For example, the unmodified, base sphingolipid ceramide acts 
as a secondary signalling molecule (11) and more complex species are implicated in 
the formation and function of signal transduction complexes (20, 24). The primary 
phosphosphingolipid species in mammalian species, including humans, is 
sphingomyelin (SM). SM is formed by the transfer of the phosphorylcholine head 
group from phospholipid phosphatidylcholine (PC) to ceramide, a reaction catalyzed 
by SM synthase (15). Unlike mammals fiingi, plants and at least some protozoa 
produce inositol phosphorylceramide (IPC) as their primary phosphosphingolipid (18). 
In these organisms IPC synthase catalyzes the transfer of phosphorylinositol from 
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phosphatidylinositol (PI) to ceramide (2, 5, 7). IPC synthase has long been established 
and studied as a target for novel anti-fungals (12, 21). More recently this enzyme 
activity has come has come under scrutiny as a potential target for anti-protozoals (31). 
With the recent identification and characterization of the Leishmania IPC synthase (7) 
it has become possible both to validate this activity as a drug target and, furthermore, 
begin to investigate the specific efficacy of known fungal IPC synthase inhibitors, and 
novel compounds, against the enzyme and the pathogen itself. Four closely related 
orthologues of Leishmania IPC synthase are apparent in the T. brucei database (7), and 
mass spectrometry of isolated fractions has revealed that whilst the predominant 
phosphosphingolipid in pathogenic bloodstream form parasites is SM; in insect stage, 
procyclic T. brucei, the primary species is, as in Leishmania, IPC (13). Here we 
describe the characterization of the model African trypanosome, T. b. brucei, 
sphingolipid synthase (TbSLS) which demonstrates itself to be a novel bi-functional 
enzyme with the ability to catalyze the biosynthesis of both IPC and SM, thus 
reflecting the sphingolipid profile of the parasite. Importandy, the IPC synthase 
activity of TbSLS is acutely sensitive to the well characterized specific fungal inhibitor 
aureobasidin A (12, 21). Furthermore, bloodstream form T. brucei are rapidly killed at 
sub-micromolar concentrations of this drug. Down-regulation of TbSLS, using 
inhibition RNA (RNAi), in bloodstream form parasites demonstrated that the enzyme 
activity is essential for growth thus validating this enzyme as a target for the 
development of new anti-HAT therapies. 
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Materials and Methods 
Sequence analyses 
Sequence alignments were made using CLUSTALW (16). Topology predictions were 
performing using the PHD package (28). 
Functional identification of Trypanosomu brucei synthase (TbSLS) 
TbSLSl (Tb09211.1000) and TbSLS4 (Tb09211.1030) were amplified with Pfii 
polymerase (Promega) from genomic D N A from T. b. brucei strain Lister 427 using 
primer pairs (homologous sequence underlined): 
TbSLS 1 - CCGGAATTCATGATTAGTTACCCTTTCTTCTCCC and 
CCGCTCGAGTCACACATACGCCCCACATTTAAAC 
TbSLS4 - CCGGAATTCATGATTAGTTACCCTTTCTTCTCCC and 
CCGCTCGAGTCATACCTCGTTAGTTGATAC 
The PCR products were subsequently cloned into the yeast expression vector pRS426 
MET to give pRS426 TbSLSl and pRS426 TbSLS4. These, together with pRS426 
ScAURl were used to transform the YPH499-HIS-GAL-AUR1 S. cerevisiae strain (7), 
and functionally complemented transformants selected on non-permissive SD medium 
(0.17% Bacto yeast nitrogen base, 0.5% ammonium sulphate and 2% dextrose) 
containing the nutritional supplements to allow selection of transformants. 
Metabolic labelling and analyses 
Logarithmic phase yeast were harvested and incubated at 10 OD60o/ml in 0.25 ml SD 
medium at 30°C for 30 minutes. The cells were subsequently incubated in SD 
supplemented with 5 | i M of NBD Ca-ceramide (Invitrogen) conjugated to fat-depleted 
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bovine serum albumen (Sigma-Aldrich) for 60 minutes. Cells were harvested by 
centrifugation and washed twice with phosphate buffered saline. Chloroform/methanol 
(0.4 ml; 1:1 v/v) was added and cells were disintegrated with glass beads. The pellet 
was re-extracted several times with chloroform/methanol/water (10:10:3). The reaction 
products were fractionated using HPTLC silica plates (Merck) and eluent system 
Chloroform:Methanol:aqueous 0.25% KCl (55:45:10). Imaging and quantification was 
carried out using a FLA3000 scanner (Fujifi lm) and AIDA Image Analyzer® software 
(version 1.3). Vero cells and untransformed Saccharomyces cerevisiae were labeled 
and processed for use as controls. Sphingomyelinase (Sigma Aldrich) was used to 
identify sphingomyelin in the NBD Q - ceramide lipids extracted from the 
complemented yeast as previously described (30). 
In vitro assay ofTbSLSl activity 
Microsomal membranes from exponentally growing YPH499-HIS-GAL-AUR1 
pRS246 TbSLS 1 were prepared as previously described (9) and the isolated membrane 
fraction re-suspended in storage buffer (50 m M Tris/HCl pH 7.4, 20% (v/v) glycerol, 5 
m M MgCh) with Complete® EDTA-free Protease Inhibitor Cocktail (Roche Applied 
Science). The protein content was determined using a Bradford assay (Brilliant Blue 
G-250, BioRad) and the concentration adjusted to adjusted to 10 mg/ml. The 
microsomal membranes were washed in 2.5% CHAPS (v/v; Sigma Aldrich; 4 °C, 60 
minutes), isolated by centrifugation (150000 g, 4 °C and 90 min), re-suspended in 
storage buffer at 10 mg/ml and stored at -80 °C until use. 
The assay assay mix contained 1 m M donor substrate (bovine liver PI, PC or PE, 
Avanti Polar Lipids), 100 m M Tris HCl, 10 m M EDTA, 6 mg/ml BSA and 200 nU 
NBD Ce- ceramide (8). The reaction was incubated at 30 °C for 60 minutes then 
quenched by the addition of 150 fA of Chloroform:Methanol:Water (10:10:3). After 
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biphasic separation the organic layer was removed dried in a rotavapor (Eppendorf 
Concentrator 5301) and resuspended in 20//I of 10:10:3 and analyszd as above. 
For inhibition experiments the reaction mix was pre-incubated for 30 minutes widi 
appropriate quantities of aureobasidin A (Takara) before the addition of NBD C6 -
ceramide. 
Agar diffusion assay 
Wild type YPH499 yeast and die transgenic sti-ain YPH499-H1S-GAL-AUR1 
complemented with ScIPCS or TbSLS were assayed for susceptibility to aureobasidin 
A (Takara), myriocin (Sigma Aldrich) and cycloheximide (Sigma Aldrich) as 
previously described (7). Briefly, 2.4x107 logarithmically dividing cells were 
embedded in 15 ml of YPD agarose (2% dextrose, 1% yeast extract, 2% peptone, 0.8% 
agarose) on lOOmnu square Petri dishes (Sarstedt). Inhibitors were applied in DMSO 
at the concentrations described below and the dishes incubated at 30°C. 
Parasite culture 
Bloodstream form T. brucei strains Lister 427 and its engineered variant. Single 
Marker Bloodstream (SMB, T7RNAP::TETR::NE0; 33) were maintained in vitro at 
37°C widi 5% C02in HMI-9 medium supplemented with 10% FCS and, for SMB, 2.5 
Hg/ml G418. 
Inhibition RNA (RNAi) of TbSLS 
An 165 base pair sequence fragment common to all four TbSLS open reading frames 
was amplified from genomic DNA using Pfii polymerase and primer pair (homologous 
sequence underiined): CATAGATCTAGAGGTTCCATACACTGTG and 
CATAGATCTAGACGAGAGGCAACGATGC 
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This PCR product was then cloned into the RNAi vector p2T7 (17), and following 
linearization, 10 ^1 transfected into SMB T. brucei and transformants selected using 2 
Hg/ml phleomycin (Sigma Aldrich). Following induction with 1 ng/ml doxycycline 
cell growth and viability were determined at 24 hour intervals by light microscopy 
using an Improved Neubauer Haemocytometer. 
48 hours post-induction total RNA was isolated (RNeasy, Qiagen) and RT-PCR 
performed (Superscript H, Inviu-ogen) using the primer pairs: 
TbSLS: AAACTGTACCTTCTTCACCG and CGAGAGGCAACGATGC 
Tb p tubulin: GGAGCGCATCAATGTGTAC and CAGGCAGCAGGTGACGCCG 
T. b. brucei susceptibility to aureobasidin A 
T. b. brucei Lister 427 were cultured in the presence of various concentrations of 
aureobasidin A. Growth and viability was analysed at 24 hour intervals as above. 
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Results 
Identification and characterisation of the T. brucei sphingolipid synthase 
Four gene sequences (Tb09211.1000, Tb09.211.1010, Tb09.211.1020 and 
Tb09.211.1030) were previously identified in the genome database (www.genedb.org) 
as sequence orthologues of the inositol phosphorylceramide synthase (LmlPCS) from 
the related kinetoplastid parasite, Leishmania (7). Like LmlPCS, TbSLS possesses 
conserved sphingomyelin (SM) synthase domains: D l , D3 and D4 (7). D3 and D4 are 
homologous to the C2 and C3 motifs in lipophophosphate phosphatases (LPP) (22) and 
domains 3 and 4 of the fungal A U R l p (14). D3 and D4 contain the histidine and 
aspartate residues that form the catalytic triad that mediates nucleophilic attack on lipid 
phosphate ester bonds (15, 22); site directed mutation of this triad inhibits both fungal 
and Leishmania IPC synthase (19); Mina and Denny, unpublished data). Further 
analysis of the T. brucei genomic sequence identified the complete open reading 
frames found on chromosome 9 which are predicted to encode four trans-membrane 
proteins with more than 90% identity and 94% similarity (figure 1). Most variation 
occurs at the carboxy-termini, a region predicted to lie on the cytosolic side of the 
membrane away from the active site at the Golgi lumen (7) with another variable 
domain close to the second predicted trans-membrane domain. One of the predicted T. 
brucei sphingolipid synthase isoforms (Tb09.211.1000; TbSLS 1) was further analysed 
in this study. However, the most distant isoform from TbSLSl (Tb09.211.1030; 
TbSLS4) with respect to the internal variable domain was also subjected to preliminary 
analyses. 
The auxotrophic mutant Saccharomyces cerevisiae strain, YPH499-HIS-GAL-AUR1, 
in which the essential A U R l IPC synthase gene is under the control of a galactose 
inducible promoter is unable to grow in the absence of galactose or the presence of the 
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repressor glucose, a phenotype that can be rescued by the expression of LmlPCS (7). 
Similarly, TbSLSl expression complemented the A U R l mutant yeast line indicating 
that it too is a functional orthologue of the yeast A U R l gene (figure 2). TbSLS4 
similarly complemented this mutant line (data not shown). 
To begin to understand the function of the T. brucei sphingolipid synthase, the 
auxotrophic YPH499-HIS-GAL-AIJR1 yeast complemented widi TbSLSl or TbSLS4 
were metabolically labelled with fluorescent NBD C6-ceramde (a substrate for 
sphingolipid synthases, including those from the kinetoplastids (7)). Under these 
conditions S. cerevisiae synthesizes a single labelled species, IPC (7). In contrast, both 
TbSLSl and TbSLS4 are shown to mediate the synthesis of two lipid species: one 
comigrated with a SM standard, the other co-migrated with an IPC standard (figure 
3A). TbSLSl was chosen for further study due to the predominance of the SM-like 
species in the complemented yeast, SM is known to be present in pathogenic 
bloodstream form T. brucei whilst IPC is only found in insect stage procyclic parasites 
(13). This species proved to be susceptible to sphingomyelinase (which specifically 
breaks down SM into phosphorylchohne and ceramide), thereby confirming its identity 
(figure 3B). These data are in support of previous mass spectrometry analyses which 
showed that the parasite harbours both SM and IPC phosphosphingolipids (13) and 
suggest that TbSLS is a novel bi-functional enzyme acting as both an SM and an IPC 
synthase. 
In vitro analyses of TbSLS] activity 
To further investigate the function of TbSLS, microsomal material isolated from the 
TbSLSl complemented yeast was used in an in vitro assay. As expected from the 
metabolic labelling studies, the addition of N B D Ce-ceramde to this lipid fraction lead, 
under the conditions employed, to the synthesis of two distinct products - one 
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comigrating with IPC; the other with SM (data not shown). In order to delineate 
enzyme function this in vitro assay was refined according to data obtained from the 
analysis of LmlPCS (Mina et al. in preparation). In brief, the microsomal fraction 
contaminated with endogenous (i.e. yeast) substrates (PI, PC, ceramide etc.) was 
washed with ice-cold 2.5% 3-[3-(cholamidopropyl) dimethylammonio]-!-propane 
sulfonate (CHAPS). This facilitated analysis of the effect of adding exogenous 
substrate to die reaction - in this case candidate donor substrates PI, PC and 
phosphatidylethanolamine (PE); plus the known acceptor substrate NBD Ce-ceramde. 
Without the addition of donor substrate the CHAPS-washed membranes demonstrated 
a relatively low level of IPC/SM synthase activity. The addition of bovine PI led to a 
large (more than 12-fold) increase in the formation of IPC demonstrating that TbSLSl 
functions as an IPC synthase (figure 4A). In contrast bovine PC and PE - donor 
substrates for SM and ethanolamine phosphorylceramide (EPC) synthesis respectively 
- had no significant effect on enzyme activity (figure 4A and B). Notably, similarly 
treated 5. cerevisiae microsomes did not respond to the introduction of bovine PI 
indicating that the yeast IPC synthase is substrate specific (figure 4C). Given the 
sphingolipid profile revealed by NBD Ce-ceramde labelling of complemented yeast 
cells and microsomes, the lack of apparent SM synthase activity following the addition 
of PC was surprising (SM synthesis; figure 4). However, when PI and PC were added 
simultaneously the quantity of IPC produced decreased 5-fold indicating that the 2 
potential donor substrates compete to bind to the same region of the enzyme, this 
affect was not seen in the ScAURl control (figure 4A and C). 
Taken together these results indicate that TbSLSl functions as an IPC synthase but 
also binds PC and participates in the syndiesis of SM. The lack of in vitro SM synthase 
activity in the presence of exogenous PC may relate to substrate specificity (see 
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ScAURl and PI, figure 4C), with the enzyme being unable to the utilize bovine liver 
PC (a mixed natural product with predominantly C36:2 PC; Avanti Polar Lipids) 
employed in the assy. In contrast, 5. cerevisiae, where both TbSLS 1 and 4 appear to 
function as SM synthases, possesses predominantly C32:2 and C34:2 PC (3). Perhaps 
TbSLS favours these relatively short acyl groups? However, T. b. brucei procyclic and 
bloodstream forms harbour significant quantities of C36, C38 and C40 PC species (23, 
26, 27), indicating that any substrate selectivity is due something more subtle. In 
support of this, although TbSLSl can utilise bovine liver PI (predominantly C38:4) 
efficiently as a subsu-ate for IPC synthesis, procyclic form parasites (known to 
synthesize IPC (13)) harbour only trace levels of the C38:4 donor substrate. 
Inhibition of TbSLS using a known anti-fungal agent 
IPC synthase is a recognized target for anti-fungal drugs and the natural product 
aureobasidin A is widely utilized and specific experimental inhibitor (29). This drug 
also specifically inhibits the activity of Leishmania LmlPCS, a TbSLS orthologue (7; 
Mina et al, in preparation) but at levels several orders of magnitude higher than those 
with the S. cerevisiae enzyme. 
Using TbSLSl complemented yeast in an agar diffusion assay it is clear that the 
enzyme is sensitive to aureobasidin A at concentrations considerably less than 25 jiM, 
and as such is less refractory to the drug than LmlPCS and similar to the yeast enzyme 
in this system (7). Cycloheximide (which inhibits protein translation) and myriocin 
(which inhibits the enzyme involved in the first step of sphingolipid synthesis, serine 
palmitoyltransferase) were used in the assay as positive controls (figure 5A). 
To establish the ICso value of aureobasidin A against the T. b. brucei enzyme the in 
vitro assay was employed using CHAPS-washed membranes with NBD C6-ceramide 
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and PI as receptor and donor substrates respectively. The syndiesis of labelled IPC was 
used as a measure of IPC synthase activity. From this assay it was evident that the 
enzyme is acutely sensitive to the drug with the activity calculated to be 50% inhibited 
(IC50) by approximately 0.2 nM aureobasidin A (figure 5B). This is comparable with 
the value for the S. cerevisiae enzyme (21). 
Validation ofTbSLS as a target of anti-protozoals 
Using a sequence fragment common to aU four TbSLS isoforms an RNAi construct 
was prepared in the p2T7 vector (17), and used to specifically inhibit their expression 
in cultured bloodstream form T. brucei (SMB). Non-induced TbSLS RNAi cells grew 
in a similar manner to control SMB parasites carrying empty vector with or without the 
doxycycline. In contrast, doxycycline induction of TbSLS RNAi saw the parasites 
cease division and led to some cell death as scored by hght microscopy. RT-PCR, 
using p tubulin as a control, confirmed the specificity of the TbSLS mRNA inhibition 
(figure 6). 
This genetic approach validated TbSLS as an essential enzyme for pathogenic 
bloodstream form parasite growth, and so a potential drug target. Given the in vivo and 
ex vivo data shown above in which aureobasidin A was demonstrated to inhibit 
TbSLS 1, the efficacy of this natural compound was tested against cultured 
bloodstream form T. b. brucei (Lister 427; figure 7). When the concentration of 
aureobasidin A was 1 cell growth was completely inhibited and the parasites were 
scored as dead by light microscopy within 24 hours. The EC50 of aureobasidin A 
against the parasites was estimated from these data as being below 250 nM. However, 
it is the typanocidal activity of this compound at higher concentrations that is of most 
significance. 
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Summary 
Previous studies using pharmacological and genetic inhibition of the first step in 
sphingolipid biosynthesis, catalysed by serine palmitoyltransferase, showed that this 
pathway is essential for the viability of both bloodstream and procyclic forms of T. b. 
brucei (10, 30). This is in contrast to the related protozoan parasite Leishmania major 
where this enzyme, though essential for sphingolipid biosynthesis, is non-essential for 
both viability and pathogenesis (6, 34). These studies indicate that sphingohpid 
biosynthesis could be a viable drug target in the African U7panosomes. 
The sphingolipid biosynthetic pathway is largely conserved across the Eukaryota 
however, whilst animal cells synthesize the phosphosphingolipid sphingomyelin (SM) 
it is known that yeast, plants and at least some of the protozoa produce inositol 
phosphorylceramide (IPC) (18). The ffC synthase of the pathogenic fungi has long 
been validated and studied as a novel drug target (12), and the recent identification of a 
functional orthologue in the protozoan Kinetoplastids, the causative agents of several 
so-called neglected diseases, has led to its consideration as a target for anti-protozoal 
agents (7). In this study we confirm that the T. brucei orthologue (TbSLS) of the 
Leishmania IPC synthase (LmlPCS) is also a functional orthologue of the 5. cerevisiae 
enzyme encoded by AURl. However, unlike the Leishmania enzyme TbSLS is able to 
catalyze the synthesis of both IPC and SM, which reflects the known sphingolipid 
content of T. brucei cells (13). Using an in vitro assay system utilizing TbSLS 1 
complemented AUR mutant yeast microsomes, it was demonstrated that the T. brucei 
enzyme was able to function as an IPC synthase. However, SM synthase activity could 
not be constituted in the same manner perhaps due to some level of specificity for the 
PC donor substrate. Notably, substrate selectivity is also demonstrated by the yeast 
enzyme, AURlp, with respect to PI. 
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The known yeast and fungal IPC synthase inhibitor, aureobasidin A, has previously 
been shown to be active against the related kinetoplast, Leishmania species, inhibiting 
growth, but not affecting viability, in culture (32). However, it has been demonsU-ated 
that the L major IPC synthase is refractory to aureobasidin A (7) and that its affect 
against the parasite in culture is non-specific (6). A similar situation has been observed 
with respect to the causative agent of Chagas disease, T. cruzi (8). In contrast, this 
study showed that aureobasidin A is specifically active against TbSLS 1 complemented 
auxotrophic AURl yeast mutant. Furthermore, the drug demonstrated a high level of 
efficacy against the parasite enzyme activity in vitro, with an ICsoof approximately 0.2 
nM. In light of these results demonstrating the ability of a specific inhibitor to affect 
enzyme activity, it was important to validate TbSLS as a potential target of anti-HAT 
drugs. Simultaneous RNAi of all four closely related isoforms of the enzyme 
demonstrated that the activity is essential of growdi and viability and so represents a 
new, much needed anti-protozoal target. Furthermore, aureobasidin A proved highly 
effective and trypanocidal against cultured bloodstream form T. b. brucei, with a 
submicromolar ECso. 
Together these data raise the possibility of the discovery of a new generation of lead 
inhibitors directed against TbSLS ultimately leading to novel drugs for the U-eatment of 
Human African Sleeping Sickness. 
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Figure Legends 
Figure 1 
The predicted amino acid sequences of the 4 previously identified T. b. brucei 
orthologues (TbSLS 1-4; Tb09211.1000, Tb092U.1010, Tb092n.l020 and 
Tb09211.1030) of the Leishmania IPC synthase are highly related demonstrating in 
excess of 90% identity. Illustrated in a ClustalW alignment. TM, TbSLSl predicted 
transmembrane domains (PHD Protein Predict); D, domains conserved with respect to 
SM synthase and Leishmania IPC synthase; * conserved residues; : highly similar 
residues;. similar residues; * residues forming catalytic triad. 
Figure 2 
Transformation with pRS426 TbSLSl rescues the auxotrophic mutant 
YPH499-HISGAL- AURl , as does pRS424 AURl . YPH499 (wild type) does not 
grow on minimal media in the absence of histidine (HIS) and uracil (URA); 
YPH499-HIS-GAL-AUR1 pRS426 (empty vector) does not grow in the presence of 
glucose. 
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Figure 3 
A. MetaboUc labelling of YPH499-HIS-GAL-AUR1 TbSLS 1 and TbSLS4 
complemented yeast with NBD Ce-ceramide showed that they are able to synthesize 2 
identifiable sphingolipid species. One co-migrated with IPC the other with SM. 
B. Sphingomyelinase (SMase) treatment of the same extract demonstrated that the 
predominant labelled species in TbSLS 1 complemented YPH499-HIS-GAL-AUR1 
contains SM. Normalized with respect to control. 
NBD C6-ceramide labelled yeast lipid extracts fractionated by HPTLC. O, origin; IPC, 
inositol phosphorylceramide; SM, sphingomyelin; Cer, ceramide (migrating at the 
front); SMase, sphingomyelinase. 
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Figure 4 
Detergent-washed microsome extracts from YPH499-HIS-GAL-AUR1 TbSLSl yeast 
demonstrate IPC synthase activity on the addition of PI, but not SM activity on the 
addition of PC. NBD C6-ceramide labelled products fractionated and quantified 
following reaction as described. All results normalized with respect to control. 
A. The addition of bovine liver PI constitutes maximal IPC synthase activity from 
TbSLSl, leading to a greater than 12-fold increase in IPC over (Control). This activity 
is 5-fold suppressed in the presence of an equimolar quantity of bovine PC. 
B. The addition of PC (nor PI or PE) did not lead to an increase in SM, indicating that 
it is not functioning as a substrate. 
C. Yeast IPC synthase activity is not induced by the addition of bovine liver PI 
indicating that whilst it is a substrate for TbSLS 1 it is not for ScAURl. 
IPC, inositol phosphorylceramide; SM, sphingomyelin; Control, no donor substrate 
added; PI, bovine liver phosphatidylinositol; PC, bovine liver phosphatidylcholine; PE, 
bovine liver phosphatidylethanolamine. 
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Figure 5 
The fungal IPC synthase inhibitor is active against TbSLS activity. 
A. Agar diffusion assay: Volumes of 1, 2 and 3 .^1 of 25 and 100 )JM Aureobasidin A 
(AbA), ImM myriocin (MYR), 25|iM cycloheximide (CYC) and DMSO as a control 
spotted onto YPH499-HIS-GAL-AURl TbSLSl plates. 
B. TbSLSl IPC synthase activity determined in vitro in the presence of aureobasidin A 
(AbA). Activity is scored as 100% in the absence of the inhibitor. The ICso was 
calculated to be approximately 0.2 nM. 
Figure 6 
TbSLS is an essential enzyme in bloodstream form T. brucei. 
A. Inhibition RNA of TbSLS. Cell counts over 48 hour p)eriod: *• Mock transfected 
cells non-induced; x Mock tranfected cells induced by 1 ^g/ml doxycline ; • TbSLS 
RNAi cells non-induced; • TbSLS RNAi cells induced by 1 |xg/ml doxycline. Error 
bars for standard deviation over three replicates are shown. 
B. RT PGR using total RNA isolated from TbSLS RNAi parasites with or without 
doxycycline induction (Deoxy). RT, reverse transcriptase. pTUB, P tubulin control. 
Figure 7 
Aureobasidin A is trypanocidal against bloodstream form T. b. brucei. Cell counts over 
72 hours with: • 1 | iM aureobasidin A (AbA); • 250 nM AbA; * control. Error 
bars for standard deviation over three replicates are shown. 
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IVMTSHPTPVDKCONPPKIENPVKNVILTVLTAGGOSIHCGDLMYSGHTVILTLHmFHW 
TMD6 D4 TMD7 
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lYOAMVHWSFRPWTWAIFGYYCIVASRSHYTDDVLVAIYLTIATFIAVGHNADGAPWQ 
**********t****it****,******** ****************************** 
ljQLFIRVa.PCCGANSREHTEDSQPVMVAFKSEELDEMNGVLEGRQKKHGGVGDGEALMFK 
LQLFIRWWPC CGANS REMTE DSQPVMVAFKS EAAGQS SRKWDERNH 
LQLFIRWLPCCGANSREVTECIGVPVAIVIKNEEMMNFEGKS 
LQLFIRWLPCCGANSREVTEDSQPVMVAFKSEAVDELRERDDSAGLSCEVSTNEV 
******* * * * * * * * * * ; * * * , ** ; . ; * . * : 
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